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ABSTRACT 
Background and Objectives: Antipsychotic medications (APMs) are used for the treatment of 
behavioural symptoms of dementia.  The use of APMs among residents of long-term care 
facilities (LTCFs), who have a high probability of dementia, is correspondingly high, and has 
been linked to adverse patient outcomes.  The study objectives were to: (a) describe facility 
variation in APM discontinuation rates, (b) test the association between time to APM 
discontinuation and patient and facility explanatory variables, and (c) conduct a sensitivity 
analysis about the effect of changes in the measurement of APM discontinuation on variable 
associations.  Methods: The study used a population-based retrospective cohort design. 
Saskatchewan’s (SK) administrative health databases for the period from April 1, 2004 to March 
31, 2011 were the data sources. The study cohort included all seniors (≥65 years of age) with a 
first admission to a SK LTCF and an APM dispensation on or after the admission date.  
Discontinuation was defined as a 70-day gap after the last APM dispensation. Patient-level 
explanatory variables included socio-demographics, comorbidity, prior medication exposure, 
behavioural and cognitive status, and health services utilization. Facility-level explanatory 
variables included size, location, licensing status, and type.  Percentage discontinuation across 
facilities was descriptively analyzed.  Cox proportional hazards regression models with 
adjustment for clustering of patients within LCTFs were used to test associations with time to 
discontinuation.  A sensitivity analysis of APM discontinuation was conducted by shortening (35 
days) and lengthening (105 days) the time from last dispensation.  Results:  Among all residents 
eligible to be cohort members 35.7% were dispensed an APM.  A total of 19.5% of the 8358 
cohort members discontinued APMs in the observation period.  The Kaplan-Meier estimate of 
the median time to discontinuation was 6.5 years.  Demographic, comorbidity, behavioural, and 
drug exposure variables were most strongly associated with APM discontinuation.  
Discontinuation was not associated with facility characteristics.  Variable associations were 
insensitive to the definition of APM discontinuation, but changed over time.  Conclusion:  
Discontinuation of APMs is low, despite high rates of utilization over long periods of time.  
Patient characteristics are associated with APM discontinuation, but not facility characteristics, 
suggesting that LCTFs are applying consistent approaches to patient management. However, low 
levels of discontinuation suggest that there may be a need for health care providers to regularly 
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review the prescribing, dispensing, and administration of APMs to LTCF residents in order to 
ensure appropriate use of these pharmaceuticals.  
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CHAPTER 1 – INTRODUCTION 
 
1.1 Background 
 
The vast majority of residents who live in long-term care facilities (LTCFs) are seniors 
(65 years of age or older), and this group of adults makes up a significant proportion of the 
Saskatchewan (SK) population.  In 2011 it was estimated that seniors comprised 15% of the 
provincial population.
1
  As this group ages it will place an increased burden on LTCFs in the 
province.
2
  The utilization rate for long-term care increases with age; provincial data show that 
the utilization rate increased from 20 to 140 beds per 1,000 population among senior aged 65-74 
years and ≥ 85 years, respectively.3  The proportion of the population that is ≥ 65 years is 
predicted to increase, with estimates ranging from 22% to 25% in the year 2036.
4
   
A serious health concern among seniors is dementia. The most common forms of 
dementia are Alzheimer’s disease (64%) and vascular dementia (19%).5,6  While the overall 
prevalence of dementia in Canada is 8%,
5
  more than half (57%) of seniors who are 
institutionalized have dementia.
5
 In clinical practice, antipsychotic medications (APMs) are used 
to manage the behavioural symptoms of dementia.
7,8
  APMs belong to one of two classes: 
conventional and atypical.
9
  Atypical antipsychotics constitute the majority of current APM drug 
prescribing in Canada because patients are less likely to experience adverse side effects like 
extrapyramidal symptoms or tardive dyskinesia.
9
  It has been estimated that between a quarter 
and a third of Canadian LTCF residents are dispensed APMs.  One study found that in the 
provinces of Manitoba, New Brunswick, and Prince Edward Island, more than one third (38%) 
of seniors residing in nursing homes were dispensed an APM.
10
  Two separate studies in Alberta 
reported APM dispensing rates of 23% and 31%, respectively.
11,12
 Antipsychotic dispensing rates 
were 24% and 32% in two studies conducted among Ontario nursing home residents.
13,14
  
However, Rochon et al. highlighted that APM prescribing rates varied considerably between 
Ontario nursing homes, from 3% to 67%.  After grouping the facilities by prescribing rate 
quintile the mean prescribing rates in the lowest and highest quintiles were 21% and 44%, 
respectively.
14
  In a SK study, it was estimated that 31% of LTCF residents were prescribed an 
APM in 2001.
15
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Observational, population-based studies of LTCF residents has identified a number of 
adverse outcomes associated with APM use including increased risk of hyperglycemia,
16-18
 
Parkinsonism,
19
 femur fracture,
20
 sudden cardiac death,
21,22
 and mortality.
20,23-28
  Randomized 
clinical trials have found that elderly patients exposed to APMs experience cognitive decline,
29
 
adverse metabolic effects (weight gain, decreased HDL, increased girth),
16
 and increased 
mortality.
30,31
  However, the causal link between APM exposure and adverse events is unclear 
because these events are also more common amongst older adults due to their unique health care 
needs.
32
  Additionally, research indicates that APM therapy has limited effectiveness for the 
behavioural and psychological symptoms of dementia (BPSD).
33-36
   
 
1.2 Statement of the Problem 
 
Research on APM use in elderly patients has focused on the initiation of APMs and 
adverse events associated with their use.  The adverse events literature has shown an association 
between APM use and outcomes such as metabolic effects, cognitive decline, fractures, sudden 
cardiac death, and mortality.  Also, randomized clinical trials have demonstrated that APM 
discontinuation is associated with a decreased mortality rate.  These two lines of evidence 
suggest that APM use may not be in the best interests of elderly patients that are not deriving 
clinical benefits from this treatment. 
Clinical practice guidelines for the use of APMs among dementia patients recommend the 
use of these agents in a safe and informed way.  The atypical APMs risperidone, olanzapine, and 
aripiprazole can be used among patients with severe Alzheimer’s disease for treating “severe 
agitation, aggression and psychosis where there is risk of harm to the patient and/or others.”37  
APMs for patients with mild to moderate dementia are cautiously recommended for the 
treatment of BPSD.
38
 
Additionally, when treating BPSD in all patients with dementia or Alzheimer’s disease it 
is recommended that “there should be periodic attempts to taper and withdraw medications after 
a period of three months of behavioural stability.”38,39  While there may be LTCF residents who 
are discontinuing APMs, there is currently no detailed description of APM discontinuation 
among elderly users of APMs in real-world settings. 
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 1.3 Purpose and Objectives  
 
The purpose of this study is to conduct a population-based investigation of APM 
discontinuation among SK seniors admitted for the first time to a LTCF, who have received an 
APM drug dispensation while residing in a LTCF.  The specific objectives are: 
1. Describe the variation in rates of APM discontinuation across SK’s LTCFs;  
2. Test the association between resident-level and facility-level factors and time to APM 
discontinuation; and 
3. Conduct a sensitivity analysis about the effect that changes in the measurement of APM 
discontinuation has on the magnitude and direction of variable associations. 
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CHAPTER 2 – LITERATURE REVIEW 
 
2.1 Medication Compliance, Persistence and Discontinuation 
 
When a medication is prescribed, the patient is expected to take it as recommended by the 
physician.  However, a patient’s drug-taking behaviour may deviate from the recommended 
treatment plan.  Compliance, persistence, and discontinuation are terms used to describe the 
degree of agreement between recommended and actual therapy.  Compliance, defined as “the 
extent to which a patient acts in accordance with the prescribed interval and dose of a dosing”,40 
is typically reported as a percentage, and is sometimes referred to as adherence.
40,41
  Persistence 
is defined as “the duration of time from initiation to discontinuation of therapy”,40 and is 
typically reported as the number of days for which therapy was available.  Discontinuation 
occurs when persistence is no longer maintained.  These definitions highlight the differences 
between compliance and persistence, particularly that compliance reflects a component of patient 
autonomy. 
 
2.1.1 APM Discontinuation 
 
Schizophrenia is an indicated use of APMs, and despite the importance of consistent 
therapy for patients with schizophrenia, it is known that many APM prescriptions are 
discontinued.  A study based on pharmacy refill records found that at the end of a nine-month 
study period, 52% and 56% of patients discontinued conventional and atypical APMs, 
respectively.
42
  Another observational study that used data from the U.S. Schizophrenia Care and 
Assessment Program,
43
  found that mean time to discontinuation among schizophrenia patients 
was 197 days for conventional APMs, and 256 days for atypical APMs.  After one year, 65% of 
conventional APM users had discontinued, compared to 45% of atypical APM users.  A 
population-based study in Maryland evaluated time to discontinuation of atypical APMs.
44
  The 
median time ranged from 54 to 61 days.  Additionally, discontinuation rates after one year 
ranged from 89.3% to 92.6%.   Finally, in Quebec a population-based study of atypical APM 
discontinuation found that 95% of patients discontinued within one year, and the median time to 
discontinuation was less than three months.
45
  Interestingly, this paper also examined patients 
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who re-initiated APM therapy (one-quarter of the sample), and found similarly high 
discontinuation rates.  While it is not expected that residents of LTCF will have discontinuation 
rates similar to schizophrenia, it is important to note that this drug utilization behaviour has been 
studied previously. 
Differences in discontinuation estimates between studies may be due to variations in the 
population under study and the operational definition of discontinuation.  For example, higher 
rates of APM discontinuation in population-based studies may be due, in part, to the definition of 
discontinuation, which considers a medication switch to be a prescription discontinuation.  
Therefore, a patient may have continued APM therapy on a different agent, but still be 
considered to have discontinued. 
Elderly patients may also be prescribed APMs for the management of behavioural 
symptoms, but recent evidence suggests discontinuing these drugs may be beneficial.  An early 
study in a single LTCF assessed how agitated behaviours changed among residents after tapering 
and withdrawal of haloperidol, thioridazine, or lorazepam.  This randomized, double blind, 
crossover study found that agitated behaviours did not worsen or improve after treatment 
withdrawal.  In Canada, a randomized clinical trial with 33 dementia patients found no 
differences in behavioural, cognition, function, mood, and extrapyramidal symptoms between 
patients randomized to APM discontinuation or continued therapy.
46
  These two studies were 
limited by their small sample sizes, which may have not had adequate power to detect 
behavioural changes.  A larger (n = 100) randomized, placebo-controlled, clinical trial of APM 
discontinuation among dementia patients found no differences between treatment groups on the 
Neuropsychiatric Inventory (NPI) total or subscale scores.  Follow-up analysis grouped patients 
above or below the median NPI value of 14.  Patients in the APM discontinuation group 
(placebo), with an NPI ≤ 14, had lower agitation scores than patients continuing APM therapy.  
Conversely, patients in the APM discontinuation group (placebo), with an NPI score >14, had 
more behavioural disturbances than patients continuing APM therapy.
47
  Similarly, a pilot study 
in a Norwegian nursing home among patients with dementia showed no significant changes in 
the NPI, or other psychometric measures, after APM discontinuation.
48
  A larger Norwegian 
study amongst residents with dementia also found that no differences in NPI total or subscale 
scores between residents randomized to discontinue or maintain APM therapy.
49
  The dementia 
APM withdrawal trial was designed to measure mortality differences between patients 
 6 
 
 
continuing vs. discontinuing APM therapy among patients with Alzheimer’s disease.  Within one 
year there was a modest elevation in mortality (5 to 8%) among patients continuing APMs.  
However, over four years of follow-up, the hazard ratio (HR) for the placebo group (compared to 
the APM group) was 0.6 (95% confidence interval [CI]: 0.4 to 0.9).
30
 Since behavioural control 
is often the goal of APM therapy among the elderly in long-term care, the APM discontinuation 
in Alzheimer’s disease trial assessed symptom relapse after risperidone discontinuation.  After 
four months of follow-up the HR for symptom relapse between patients discontinuing vs. 
maintaining risperidone was 1.94 (95% CI: 1.09 to 3.45).  Over the subsequent four months the 
HR increased to 4.88 (95% CI: 1.08 to 21.98).
50
  This research suggests that APM 
discontinuation increases the risk of symptom relapse among patients that have responded to 
risperidone treatment.  Collectively, the research studying the effects of APM withdrawal shows 
that both benefits (improved survival) and risks (symptom relapse) exist. 
Despite the limitations of clinical trials, like small sample size and highly selected 
populations, observational studies about APM discontinuation among elderly patients are rare.  
Kleijer et al. analyzed the pattern of behavioural problems of elderly residents of LTCFs 
diagnosed with dementia using data from the Minimum Data Set (MDS), a clinical assessment 
tool.
51
  Problem behaviours were measured with the MDS-Challenging Behaviour Profile 
(CBP).
52
  Three months after APM discontinuation 30% of patients had improved problem 
behaviours while 32% had deteriorated.
51
  The paucity of research about APM discontinuation 
among elderly care home residents in the real world highlights the need for a deeper 
understanding of this issue. 
 
2.1.2 Medication Discontinuation among the Elderly 
 
Despite the lack of research about APM discontinuation among elderly patients, there are 
studies examining discontinuation of other types of drugs in this population.  Cholinesterase 
inhibitors are used to treat dementia, and in a SK population-based study the median time to their 
discontinuation was 191 days.
53
  After one year of follow-up 66.4% of the sample had 
discontinued treatment.  In France, an observational cohort study evaluating cholinesterase 
inhibitor use found that 54.7% of patients had discontinued after one year of follow-up.
54
  A 
population-based study in Quebec examined oral bisphosphonate discontinuation, agents used to 
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treat osteoporosis.
55
  Approximately 65% of patients discontinued their prescribed oral 
bisphosphonate within one year of follow-up.  A limitation of these studies is that they use 
community-dwelling populations, which does not reflect the prescriber/staff treatment intentions 
that would likely exist within a LTCF.  Benzodiazapines are also used in the LTCF setting, and a 
small Italian study reported on benzodiazepine discontinuation.
56
  Among these patients 17.3% 
of benzodiazepine users discontinued therapy, mainly within the first year of follow-up.  It is not 
clear if the lower discontinuation rate observed in this study is an effect of the LTCF, the drug 
under study, or between-country differences.   Overall, discontinuation varies between drug 
classes, and the effect that residing in a LTCF has on discontinuation is unknown. 
 
2.2 Predictors of APM Utilization and Variation in Long-term Care Facilities 
 
Antipsychotic utilization can be influenced by characteristics of the individual patient, as 
well as facility and physician characteristics that comprise the external environment of a LTCF 
resident.  Assessment of the association of individual- and facility-level factors on the probability 
of initiating, persisting, and discontinuing an APM prescription can contribute to an 
understanding of how these drugs are utilized among residents of LTCFs. 
 
2.2.1 Patient Predictors of APM Utilization 
 
Patient socio-demographic, comorbidity, behavioural, and other medication use 
characteristics have been tested for their association with APM utilization, but these studies have 
not always produced consistent findings. 
Increasing age has been associated with a lower likelihood of APM utilization.
57-59
  
However, inverse associations between age and utilization have not been consistently 
identified,
10,13
  The relationship between sex and APM utilization is also unclear.  Some studies 
have found lower utilization among women, 
13,59
 while others have found lower utilization 
among men,
10,60
 or no differences.
57
  With respect to ethnicity, lower prescribing rates have been 
noted among Caucasians.
59
   
The presence of comorbid conditions may be both positively and negatively associated 
with APM utilization. Higher scores on the Charlson Comorbidity Index, a global measure of 
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comorbidity, have been linked with a lower likelihood of APM dispensation.
13
  Conversely, the 
presence of a dementia diagnosis is strongly associated with APM use.  Eighty-nine percent of 
Swedish LTC residents with dementia were prescribed an APM, while 59% of residents without 
dementia received these agents.
60
  In an Ontario study, the odds of a LTCF resident receiving an 
APM were 3.52 (95% CI: 3.24-3.82) times higher among patients with a history of dementia.
13
  
A descriptive study from the United Kingdom found that 32% of participants with dementia 
received an APM, compared to only 10% without dementia.
61
  In the USA, a recent study found 
that 69% of residents with dementia diagnosis and 31% of residents without a dementia 
diagnosis were receiving an APM.
59
  Psychosis has also been noted as a predictor of APM use.
59
 
Behavioural measures have also been linked to APM use.  Frailty, which has been 
measured with the Changes in Health, End-Stage Disease and Signs and Symptoms (CHESS) 
scale, was found to have an inverse association with APM prescribing rates.
59
 Impaired 
cognition, using the Cognitive Performance Scale (CPS), was associated with lower APM use.
59
  
Conversely, severe behavioural problems, measured using the Behaviour Index, were positively 
correlated with APM use.
59
  The literature indicates that patients with complex care needs are 
less likely to receive an APM, but APM use is very likely among patients with a brain disease 
like dementia or psychosis. 
 Polypharmacy, the use of multiple concurrent medications, can influence the decision of 
a physician to prescribe an APM, and also the patient’s decision to adhere to treatment.  A 
patient’s medication history is often used as a predictor variable in APM utilization research, but 
the estimate of the effect has not been reported.
14,23,62
  A literature review of medication 
adherence among seniors identified an inverse relationship between the number of drugs 
prescribed and adherence, which was one of the most consistent determinants of adherence 
identified. 
63
 
 
2.2.2 LTCF Predictors of APM Utilization 
 
Characteristics of LTCFs that have been investigated for their association with APM 
utilization amongst institutionalized residents include size, staffing, geographic location, 
prevalence of psychotropic drugs, and disease prevalence. No consistent relationship between 
facility size and APM use has been described, with studies finding both no association,
57
 and 
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decreased APM use with increased facility size.
64
  The number of nursing staff in a facility has 
not been correlated with APM prescribing tendencies.
57,64
  Some studies have identified that an 
increased availability of physicians is linked with higher APM prescribing rates,
64
 but other 
studies have failed to confirm this association.
57
  Additionally, the presence of nursing assistants 
was found to be negatively correlated with APM use, but the assistant-to-nurse ratio was 
positively correlated.
64
  In the US, variations in APM prevalence has been observed, with the 
highest rates in the Northern United States.
64
  The prevalence of other psychotropic agents like 
anxiolytic, hypnotic, and antidepressant use has been positively correlated with APM 
prevalence.
64
  Finally, prevalence of dementia, behavioural symptoms, or psychiatric diagnoses 
was found to be positively associated with APM prevalence, while depression was negatively 
correlated.
64
  
 
2.2.3 Variation amongst LTCFs in APM Utilization 
 
Quantifying variation in APM utilization rates amongst facilities may contribute to an 
understanding of potential overuses of APMs.  Variation has been described in previous research 
by dividing facility-level APM prescribing into quintiles; an Ontario study showed that the 
relative risk (RR) of dispensation between individuals in the highest and lowest quintiles was 3.0 
(95% CI: 2.74-3.19).  When the analysis stratified patients by the presence of diagnosed 
psychosis, dementia but no psychosis, and no dementia or psychosis the RR was 2.7 (95% CI: 
2.35-3.09), 3.1 (95% CI: 2.81-3.39), and 2.9 (95% CI: 2.19-3.81), respectively.
14
  A similar US 
study found that the RR of APM use in the highest versus lowest use facilities, after adjusting for 
facility and residents characteristics, was 1.37 (95% CI: 1.24-1.51).  However, among residents 
with psychosis the RR was not statistically significant (RR = 1.14, 95% CI: 0.98-1.33).  The 
elevated risk of APM therapy among high prescribing facilities was influenced by whether 
residents had dementia without psychosis (RR = 1.40, 95% CI: 1.23-1.59) or neither psychosis or 
dementia (RR = 1.54, 95% CI: 1.24-1.91).
59
 
Variation in APM use has also been evaluated by studying differences in prescribing 
tendency between atypical and conventional APMs.  A cross-sectional study using national MDS 
data from five US states evaluated the relative use of atypical to conventional APMs.  Overall, 
the authors concluded that clinical and demographic differences between atypical and 
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conventional APM users tend to be relatively small, suggesting that facility, physician, and 
economic forces may influence the choice of APM.
65
  A recent study quantified between-facility 
variation for prescribing of atypical vs. conventional APMs using a random-effects regression 
model.  Patient and facility fixed effects accounted for 36% and 23% of the explained variance, 
respectively.  A random intercept representing the conventional APM prescribing rate accounted 
for 81% of the explained variation.
62
 
 
2.3 Summary and Conclusions 
  
Discontinuation of APMs at the population level has mainly been studied among patients 
with schizophrenia.  However, the duration of APM use, and its associated influences, are likely 
different when studying APM discontinuation in LTCF residents.  In this regard, very little has 
been published, but some studies have examined the effects of APMs.  Among older users of 
APMs, randomized clinical trials have demonstrated a survival benefit of discontinuing these 
pharmaceuticals, although some patients may be at risk of relapsing symptoms.  Research 
examining the utilization of APMs among older patients appears to have focused on the initiation 
or the level of prevalent use of these agents.  Dementia is a strong predictor of APM use among 
older LTCF residents.  Other individual factors that may also influencing APM use are socio-
demographic, disease comorbidity, polypharmacy, and psychological or behavioural problems.  
LTCF factors were also identified that may influence APM utilization, including facility size, 
staffing, and geographic location.  Variation in facility-level APM prevalence has been 
documented.  However, how patient- and facility-level factors influence this variation has only 
been described in the context of the choice of initial APM agent.  In conclusion, APM 
discontinuation among elderly LTC residents and the predictive role of patient and facility level 
factors, from a population-based perspective is largely unknown at this time.
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CHAPTER 3 – METHODS 
 
3.1 Data sources 
 
Saskatchewan’s administrative health databases were used to conduct this research.  
Saskatchewan, like other Canadian provinces, has a program of universal health care, which 
covers a population of approximately 1.03 million people according to the 2011 Statistics 
Canada Census.
1
  All members of the covered population receive health insurance benefits, 
which includes physician and hospital services, coverage for a large number of prescription 
medications listed in the provincial formulary, homecare, and access to long-term care for a user 
fee based on income.
66
  Some individuals (members and veterans of the Canadian Forces, Royal 
Canadian Mounted Police, and federal inmates)
67
 are not eligible for provincial health coverage, 
but make up a less than 1% of the population.  Additionally, registered Indians (approximately 
9% of the population) do not have their prescription drug costs covered by the province because 
coverage is provided by a federal health benefits program.
68,69
 
The specific databases used for this research were the: Person Registry System (PRS), 
Discharge Abstracts Database (DAD), Medical Services Database (MSB), Prescription Drug 
Database (PDD), Institutional Supportive Care Home (ISCH) database, and the Resident 
Assessment Instrument – Minimum Data Set (RAI-MDS).  All databases can be linked using a 
unique, anonymous, personal identifier to create a longitudinal healthcare utilization history for 
each person.  These databases are maintained by the provincial Ministry of Health and were 
accessed at the SK Health Quality Council. 
The PRS contains information pertaining to dates of health insurance coverage, birthdate, 
sex, and location of residence.  The DAD contains records of hospitalizations and is produced 
upon discharge.  At the start of the 2002/03 fiscal year (fiscal year is April 1 to March 31)  a 
maximum of 25 five-digit diagnosis codes using the Canadian version of the tenth revision of the 
International Classification of Diseases (ICD-10-CA) are available for all hospital discharge 
abstracts.
68
  Physician services remunerated on a fee-for-service basis are captured in the MSB; 
each billing claim contains a single three-digit ICD-9 code.
68
  Some physicians receive a salary, 
and their services are not consistently collected because not all salaried physicians submit these 
administrative claims.
70
  The PDD, which captures all dispensations of medications on the 
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provincial formulary, contains drug dispensation date, American Hospital Formulary Service 
(AHFS) Pharmacologic-Therapeutic Classification System 
(http://www.ahfsdruginformation.com/class/index.aspx), drug identification number (DIN), 
medication strength, dosage form, and quantity dispensed.
68
  Individuals accessing the province’s 
long-term care system have their program type, admission and discharge dates, and level of care 
requirements recorded in the ISCH database.  In addition to resident characteristics, this database 
contains facility specific information such as location, affiliation, licensing status, and type of 
facility.  Facility size, reported as the number of beds, and was provided directly by the SK 
Ministry of Health as data tables for each fiscal year. 
Beginning April 2001 it was mandatory for all LTCFs to complete clinical assessments of 
their residents using the RAI-MDS 2.0.  This tool collects information about a resident’s 
functional, medical, psychiatric, and social status upon admission to a LTCF.
71
  Assessments are 
also conducted quarterly, annually, and when a major change in health status occurs.
71
  The 
quarterly assessments are a subset of the full RAI-MDS instrument.
71
  
Several studies have found the reliability and validity of SK’s administrative health 
databases to be good for population health and health services research.
72-78
  Additionally, these 
databases have been used to study the pharmacoepidemiology of psychoactive drugs such as 
antidepressants, benzodiazepines, and APMs.
79
 
 
3.2 Cohort design 
 
The target population for this retrospective cohort study was seniors (≥ 65 years of age) 
that were dispensed an APM during their first episode of residence (EOR) in a SK LTCF, 
between April 1, 2004 and March 31, 2013.  The EOR was defined as the time from LTCF 
admission until the first study end point:  death, end of provincial healthcare coverage, LTCF 
discharge, or end of the study period.  The EOR is the observation period during which APM 
discontinuation is evaluated among the cohort members.  Only the first EOR was examined, to 
maintain a focus on incident users of long-term care.  Residents starting their first EOR after 
April 1, 2012 were excluded.  This criterion was used to provide all cohort members with the 
opportunity to have up to a minimum one year EOR (i.e., until the study ended on March 31, 
2013). 
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Cohort members were required to be registered in the long-term care program, thereby 
excluding individuals accessing only the day care or temporary/night care programs.  If an 
individual participated in either of these programs, as well as the long-term care program, only 
the records pertaining to long-term care were considered further.  Also, if a resident was younger 
than 65 years of age when their first EOR began they were excluded because younger residents 
are fundamentally different than older residents.
80
  For example, younger users of LTCFs have 
fewer deficits in daily living scores, lower use of mobility aids, fewer sensory impairments, and 
are more likely to have cognitive deficits than older residents.
80
  Residents were also required to 
have one year of provincial healthcare coverage prior to the start of the first EOR in order to 
describe their disease comorbidities and pharmaceutical exposures.  Some residents (3.9%) had 
gaps in health care coverage, and a gap between records of ≤ 90 days was considered continuous 
coverage, and a gap > 90 days was considered a loss of coverage.  The majority of the gaps 
(77.5%) were only a single day. 
Information on death and end of provincial healthcare coverage dates were obtained from 
the vital statistics and PRS databases, respectively.  The date of LTCF discharge was obtained 
from the ISCH database. Each resident was first required to have a continuous record of LTCF 
residence.  This was required because sequential ISCH records were observed to occur 
simultaneously in time, and these cases were classified as overlapping or nested records.  Two 
records were overlapping when the first record’s discharge date occurred after the second 
record’s admission date.  In these cases a continuous EOR was created by assigning the 
discharge date of the first record to the day prior to the admission date of the second record.  A 
record was nested if the admission and discharge dates of one record were contained within the 
period between the admission and discharge dates of another record.  The record that had the 
larger amount of time was retained to eliminate nested records.  These changes to overlapping 
and nested records did not result in the exclusion of any individuals, and allowed the LTCF 
discharge date to be determined.  When a gap of ≥ 1 day existed between the discharge and next 
admission dates the resident was deemed to be discharged.  Additionally, if a resident transferred 
LTCFs more than 60 days after the start of the EOR then the resident was considered to be 
discharged.  However, transfers within 60 days of the EOR start date were considered a 
continuation of the same EOR.  Transfers were defined as two continuous ISCH records with a 
change in the LTCF identifier within a 60 day period. This is because admission to a LTCF in 
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SK is based upon the first available bed, and may not be the preferred LTCF of the resident.
81
  
When a bed becomes available in the residents preferred LTCF the resident is permitted to 
transfer to that facility.  Among transferring residents, the first transfer occurred for most 
(74.5%) within 60 days of LTCF admission.  Residents with multiple transfers usually 
experienced their secondary transfers more than 60 days after admission to a LTCF (63.9%).  
To evaluate APM discontinuation it was necessary for each resident to be dispensed a 
minimum of one APM after the start of the first EOR.   For some residents the first APM 
dispensation occurred after the EOR ended; these residents were excluded because they were not 
eligible to discontinue an APM in the cohort observation period.  Similarly, residents that were 
dispensed an APM on the same day their EOR ended were excluded. 
 
3.3 Measures 
 
3.3.1 Outcome variable 
 
The outcome variable, time to APM discontinuation, was derived from the data contained 
within the PDD.  All drugs assigned the AHFS code for APMs (28:16.08) covered by the SK 
drug plan during the study period were identified.  The generic names of these drugs were 
collected, and included: chlorpromazine, clozapine, flupenthixol, fluphenazine, haloperidol, 
loxapine, mesoridazine, olanzapine, pericyazine, perphenazine, pimozide, pipotiazine, 
prochlorperazine, quetiapine, risperidone, thioridazine, thiothixene, trifluoperazine, ziprasidone, 
and zuclopenthixol.  Additionally, the APM methotrimeprazine was manually included in the 
generic drug name list because it was classified as a miscellaneous agent (AHFS 28:24.92).  A 
list of all APMs covered by the SK drug plan during the study period is included in Appendix A.  
Using the generic drug names a list of all associated DINs were identified.  Since DINs uniquely 
identify all drug products sold in Canada,
82
 all dispensations for APM agents were identified 
from the DIN list by linking them with the complete set of dispensation records for cohort 
members.  All dispensations for the agent prochlorperazine were excluded because this agent is 
primarily used as an anti-nausea agent. 
The date of the first APM dispensation was defined as the index date.  Cohort members 
were considered persistent users of APMs until the exposure period from their last dispensation 
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had elapsed, which was 35 days after the last APM dispensation date.  Therefore, the APM 
discontinuation date was 35 days after the last APM dispensation date.  Thirty-five days was 
chosen because dispensations to residents of LTCFs are commonly filled for the entire LTCF 
approximately once a month.  This was supported by the dispensation data in this study, where 
18.9% and 38.5% of subsequent APM dispensations were separated by 22-28 and 29-35 days, 
respectively.  Additionally, 85.0% of all subsequent dispensations were separated by ≤ 35 days. 
The time to event for each cohort member was the time between the first APM 
dispensation, and the earliest study end point.  The endpoint under study was APM 
discontinuation.  To establish APM discontinuation a 35 day non-exposure period was added to 
the discontinuation date, and required to elapse, without any alternative endpoints occurring.  
Therefore, residents were only considered a discontinued APM user if their EOR did not end 
within 70 days of the last APM dispensation date.  If this condition was not met the resident was 
considered to be right censored (Figure 3.1). 
 
3.3.2 Explanatory variables 
 
3.3.2.1 Patient-level explanatory variables 
 
Explanatory variables included demographics, comorbidity, behavioural characteristics, 
drug exposures, and health care utilization.  The demographic variables of age and sex were 
defined from the PRS on the cohort entry date.  Age was grouped as 65-74, 75-84, 85-94 and ≥ 
95 years of age.
83
  Additionally, the fiscal year of the index APM dispensation was included in 
this variable group.   
The Charlson index,
84
  the number of distinct prescription medications,
85
 and level of 
care were selected as measures of disease comorbidity.  The Charlson index was defined using 
all diagnoses captured in the hospital DAD and physician MSB in the one-year period prior to 
the cohort entry date.  The Charlson index scores were categorized as 0, 1-2, 3-4, and 5 or more, 
as per the original publication.
84
  All medications covered by the PDD are grouped by a six-digit 
AHFS code, and these groups were considered to be the same medication.  The total number of 
unique prescription medications used within the year prior to the cohort entry date was a measure 
of disease comorbidity, and categorized as 0-3, 4-6, and 7 or more distinct prescription 
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medications.  Level of care was determined from the ISCH database at the time of LTCF 
admission, and categorized into four levels: (1) level 1 (supervisory care) and level 2 (limited 
personal care), (2) level 3 (intensive personal / nursing care), (3) level 4a (specialized 
supervisory care, emphasis on management of advanced mental deterioration), and (4) level 4b 
(supportive care), level 4c (restorative care), and level 4 unclassified.   
Psychiatric comorbidities were also identified, and were defined from diagnosis codes in 
the DAD or MSB within one year of the cohort entry date. These included dementia (including 
Alzheimer’s disease), mood disorders (i.e., depression and anxiety), alcohol and drug use, 
schizophrenia, and movement disorders (i.e., Parkinson’s disease, Huntington disease, and 
movement tics).
13,14,86
  The ICD codes used to select these comorbid conditions are reported in 
Appendix B.  
Behavioural disturbances and cognitive status of LTC residents was determined using the 
MDS-Challenging Behaviour Profile (MDS-CBP)
52
 and the MDS-Cognitive Performance Scale 
(MDS-CPS)
87
, respectively.  The MDS-CBP is a 16-item scale ranging from 0 to 30, derived 
from sections E, B, and F of the full RAI-MDS assessment.  The full MDS assessment is 
completed upon admission to a LTCF, when major changes in functional status occur, and on an 
annual basis.
71
  We considered the MDS-CBP score upon admission to a LTCF.  The MDS-CBP 
score was categorized as: none (MDS-CBP = 0), mild (MDS-CBP = 1 to 4), moderate (MDS-
CBP =5-9), severe (MDS-CBP = 10-14), and extreme (MDS-CBP ≥ 15).51  The MDS-CPS 
provides a measure of cognitive impairment using five MDS items that classifies patients to one 
of seven groups, ranging from 0 (intact) to 7 (very severe impairment) that correlates with the 
Mini-Mental State Examination.
87,88
  The MDS-CPS scores were grouped to categorize each 
resident as minimally impaired (0-1), moderately impaired (2-3), and severely impaired (4-6).
59
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Figure 3.1 1Characteristics of time to APM initiation, time to event, and EOR among residents that discontinued 
APMs (A) or were right censored (B).Time to APM initiation (t0 – tLTCF), time to event (discontinue APM: td – t0; 
right censored: ta – t0), and EOR (ta – tLTCF). 
Psychotropic drug use was determined from the PDD, and included exposure to 
benzodiazepines, antidepressants, anticholinergic agents, cholinesterase inhibitors, and APMs.  
These drugs were examined in the year prior to the cohort entry date to evaluate the most recent 
exposure, and were grouped as not used, prior user, and current user.  A drug was considered not 
used when there was no dispensation record for the specific agent.  A prior user had their last 
dispensation more than 30 days before the cohort entry date, while a current user had a 
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dispensation within 30 days of the cohort entry date.  Finally, the time to APM initiation was 
defined as the number of days between LTCF admission (i.e., cohort entry date) and the index 
date.  Time to initiation was classified as 0-30 days, 31-90 days, and > 90 days.  Psychotropic 
drugs covered by the SK drug plan during the study period are reported in Appendix A. 
Health care utilization was measured by LTCF transfers and hospitalization.  The transfer 
status (yes/no) of a LTCF resident was evaluated during the first 60 days after the cohort entry 
date (see section 3.2). Hospitalization for more than one day in the year prior to the cohort entry 
date and after the index date was defined using the DAD.   
 
3.3.2.2 Facility-level explanatory variables 
 
Characteristics describing features of LTCFs was their licensing status, affiliation, type, 
location, and size; these characteristics were assigned based on the index date for the resident.  
Facility size was exclusively contained within the data provided by the Ministry of Health, and 
was defined by the number of long-term care beds classified as small (1-35 beds), medium (36-
100 beds), or large (> 100 beds).  The location of the LTCF was defined by the health region it 
was located within, and was grouped as the Regina Qu’Appelle Health Region, Saskatoon Health 
Region, or other health region.  The other health region group included 11 health regions that do 
not contain a major urban centre.  There were four types of facilities: health centres, hospitals, 
special care homes (nursing home), or integrated facilities.  Health centres, hospitals, and 
integrated facilities are considered a type of LTCF because in smaller, rural centres they have 
dedicated long-term care beds.  Each facility’s affiliation was classified as affiliate (operated 
privately, non-profit), contract (operated privately for profit), or amalgamate (operated publicly, 
by the health region).  Additionally, facilities were identified as either licensed or non-licensed.  
For some residents the facility affiliation or licensing variables were missing.  Since this 
information was also recorded within the datasets containing facility size information, the 
missing values were replaced with the values from this data source. 
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3.4 Descriptive analysis 
 
The cohort was described on resident- and facility-level characteristics using counts, 
means, and medians, as appropriate.  These results were stratified by APM discontinuation status 
(i.e., discontinued vs. continued).  Utilization characteristics of APMs were evaluated between 
the first dispensation and the end of follow-up for each individual.  The number of dispensations, 
the largest time between two dispensations, the type of index APM, and switching between 
APMs were reported. Facility-specific discontinuation percentages were calculated by dividing 
the number of residents discontinuing APMs by the total number of residents of a facility.   
Each resident was assigned to a quintile based on the length, in days, of their EOR.  The 
proportion of cohort members that discontinued APMs within each quintile was calculated.  
Additionally, each individual was divided into quintiles based on the length of time to event, in 
days.  The proportion of total discontinuations within each quintile was used to understand when 
discontinuations were occurring relative to the first APM dispensation. 
APM discontinuations were also described by their frequency, and average and median 
time to event.  Additionally, adjusted estimates of the average and median time to APM 
discontinuation were calculated using the non-parametric Kaplan-Meier (KM) method.  The 
probability of APM discontinuation was described using non-parametric survival functions. 
3.5 Inferential analysis 
 
Semi-parametric Cox proportional hazards regression models were used to analyse the 
time to event data.  Since cohort members were residing within LTCFs, it is possible the 
independence assumption is violated.  This assumption was investigated using a Cox regression 
model with a random effect for facility.  Two such models were run, the first without any 
predictors and the second with the fully adjusted model with covariate time interactions.  
Individuals with missing values for any of the explanatory variable were excluded, leaving 7361 
individuals from the cohort of 8358 for analysis.   
Univariate models were used to describe the unadjusted effect of each covariate.  
Partially adjusted models included sets of variables: demographics, health status, behavioural 
characteristics, drug exposure, health care utilization, and LTCF measures.  The baseline 
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partially adjusted model included only the demographic variables, which were age, sex, and 
index fiscal year (i.e., year first APM was dispensed).  All other partially adjusted model 
included this set of demographic variables, in addition to another variable group.  In addition, 
sequentially adjusted models incorporated each variable group one at a time to produce a fully 
adjusted model containing all covariates.  Reference categories for all explanatory variables were 
indicated within the tables reporting model results. 
The proportional hazards assumption was assessed for the fully adjusted model by testing 
the correlation between the scaled Schoenfeld residuals and the rank order of the event times for 
a non-zero slope (Appendix C, Table C1).  In addition, three graphical methods were used to 
confirm the presence of non-proportional hazards.  Specifically, the KM probability of APM 
discontinuation was plotted against time, in days.  The KM log cumulative hazard plot and the 
scaled Schoenfeld residuals were plotted against the natural logarithm of time to event (days).  A 
covariate-time interaction was added to the fully adjusted model for all variables that violated the 
proportional hazards assumption, to produce the final analytic model.  Further interactions were 
not pursued for two reasons.  First, all predictor variables were categorical which would increase 
the total number of estimated parameters substantially, and possibly result in over-fitting the 
model.  Second, since non-proportional hazards were present the parameter estimates of 
interaction terms could be biased.  
The models were compared using the Akaike Information Criterion (AIC), the Schwartz-
Bayesian Criterion (SBC), and the likelihood ratio test (LRT).  The LRT is a test of the global 
null hypothesis that the parameter estimates of the model with more predictors are equal to zero.  
A significant test statistic indicates that one or more of the covariates are significantly associated 
with APM discontinuation.  The AIC and SBC are related to the LRT, but penalize the log 
likelihood according to the number of model parameters included (i.e., all covariate levels).  An 
improvement in the fit of the model is detected by a lower value of the AIC or SBC statistics. 
 The discrimination of the partially and sequentially adjusted models was measured using 
the c-statistic, which is based on observed and predicted survival.
89
  If the c-statistic has a value 
of 0.5 it indicates that the model prediction is no better than chance, while a value of 1 represents 
perfect prediction.
90
  A c-statistics in the range of 0.7 to 0.8, 0.8 to 0.9, and greater than 0.9 
represent acceptable, excellent, and outstanding  discriminative performance, respectively.
91
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Other tests of model fit included an evaluation of outliers (Figure D1) and influential data 
points (Table D1) using deviance and scaled score residuals, respectively (Appendix D).
92
  
Hazards ratios (HRs) were reported, along with estimated 95% CI.  For the fully adjusted model 
with covariate time interactions the HRs were calculate from the model and reported for the 
variables with non-proportional hazards at 0, 90, 180, 365, and 730 days.  All analyses were 
conducted using SAS 9.3 using the PHREG procedure, and normally distributed random effects 
were incorporated with the inclusion of a RANDOM statement to account for clustering of 
individuals within LTCFs.  
3.6 Sub-group and sensitivity analyses 
 
Sub-group analyses were performed for the variables characterizing dementia diagnosis, 
schizophrenia diagnosis, transfer to a new LTCF, prior APM dispensation, and time to APM 
initiation.  These sub-group analyses were conducted for the analysis of discontinuation within 
the EOR and time to event quintiles.  
Sensitivity analyses were used to assess changes in the results due to informative 
censoring, violation of proportional hazards, and changes in the measurement of time to 
discontinuation.  The non-informative censoring assumption of the Cox proportional hazards 
model was evaluated with sensitivity analyses for two extreme violations of this assumption.  
Complete positive correlation between the censoring and APM discontinuation time was created 
by assigning all censoring times to be equal to the APM discontinuation date.  Second, by 
assigning the APM discontinuation date to be equal to the longest time to event for censored 
individuals, complete negative correlation between censoring and APM discontinuation dates 
was induced in the data.  When the proportional hazards assumption was violated, a sensitivity 
analysis during a period when hazards were proportional was performed by truncating follow-up 
at 6 months.   
Two alternate definitions of APM discontinuation were incorporated to assess the impact 
on the outcome variable and analytic results.  Like the primary definition of APM 
discontinuation both alternate definitions maintained the 35 day exposure period after the last 
APM dispensation.  But they differed by shortening or lengthening the non-exposure period.  
When the non-exposure period was shortened to 0 days, residents were classified as 
discontinuing APMs if their EOR did not end before 35 days had passed since the last APM 
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dispensation.  When the non-exposure period was lengthened to 70 days, only those  individuals 
whose EOR did not end before a total of 105 days had passed since the last APM dispensation 
were classified as discontinuers. 
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CHAPTER 4 – RESULTS 
4.1 Description of study cohort 
 
A total of 88,016 individuals were eligible to enter the study cohort based on the criteria 
of having at least one record in the long-term care (i.e., ISCH) database.  After applying all study 
exclusion criteria (Figure 4.1) a total of 8358 were retained in the cohort, which represent 35.7% 
of LTCF residents eligible to be dispensed an APM.  There were 6729 (80.5%) members of the 
cohort that had continuous use of APMs during the observation period, and 1629 (19.5%) 
discontinued APM use during the observation period. 
 
 
 
Figure 4.1 1Study population flow chart detailing exclusion criteria. 
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The patient characteristics of the cohort are described in Table 4.1.  The average age was 
84.5 years (SD = 7.1) and nearly two-thirds of the cohort (63.2%) was female.  The Charlson 
index score had a mean of 1.8 (SD = 2.1), and three-quarters (74.7%) of the cohort had a score 
between zero and two, indicating low comorbidity.  Polypharmacy was common in the year prior 
to LTCF admission, with 53.3% of residents having dispensations for seven or more different 
drugs.  The level of care was concentrated in the second category, indicating the provision of 
intensive personal or specialized supervisory care.  Among psychiatric comorbidities, dementia 
(46.7%), schizophrenia (53.0%), and mood disorders (29.3%) were commonly recorded.  
Approximately half of the cohort (52.6%) had an MDS-CPS score indicating moderate cognitive 
impairment.  The MDS-CBP scores indicate that most cohort members had mild (36.7%) or 
moderate (26.0%) levels of challenging behaviour on their first RAI-MDS assessment.  At least 
half of the cohort did not have exposure to APMs (50.7%), antidepressants (66.2%), 
benzodiazepines (74.1%), anticholinergic agents (87.9%), or cholinergic agents (88.5%) in the 
year prior to LTCF admission.  There were 4123 cohort members with APM exposure prior to 
admission to a LTCF, and 71.2% of them had their most recent dispensation within 30 days of 
admission.  Most members of the study cohort (58.1%) were dispensed their first APM within 30 
days of their LTCF admission date.  The median time to APM initiation was 22 days.  Within 90 
days of LTCF admission, three-quarters (76.6%) of the cohort members had been dispensed their 
first APM.  After admission, transfers between LTCFs occurred for approximately one-third 
(35.5%) of the cohort members.  Hospitalization was common (69.7%) before LTCF admission, 
but less frequent after admission (41.7%).   
In terms of the characteristics of facilities in which the cohort members resided, the vast 
majority of residents were in licensed LTCFs (94.4%) and facilities defined as special care 
homes (89.8%) (Table 4.2).  Nearly half of these LTCFs were located within either the 
Saskatoon (25.9%) or Regina Qu’Appelle (18.8%) health regions and half (56.6%) were 
operated as amalgamates (i.e., publicly run).  Medium (36-100 beds) and large (> 100 beds) 
facilities were the most common size of LTCF in which the study cohort resided. 
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Table 4.1 1Patient characteristics of the study cohort. 
Variables 
Overall 
(N = 8358) 
APM 
Discontinued 
(N = 1629) 
APM  
Continued 
(N = 6729) 
Demographic n (%) n (%) n (%) 
Age    
 65-74 years 903 (10.8%) 163 (10.0%) 740 (11.0%) 
 75-84 years 3219 (38.5%) 594 (36.5%) 2625 (39.0%) 
 85-94 years 3770 (45.1%) 783 (48.1%) 2987 (44.4%) 
 95+ years 466 (5.6%) 89 (5.5%) 377 (5.6%) 
Sex    
 Female 5285 (63.2%) 1094 (67.2%) 4191 (62.3%) 
 Male 3073 (36.8%) 535 (32.8%) 2538 (37.7%) 
Index fiscal year    
 04/05 792 (9.48%) 163 (10.0%) 629 (9.4%) 
 05/06 940 (11.2%) 221 (13.6%) 719 (10.7%) 
 06/07 1014 (12.1%) 229 (14.1%) 785 (11.7%) 
 07/08 1041 (12.5%) 204 (12.5%) 837 (12.4%) 
 08/09 1043 (12.5%) 243 (14.9%) 800 (11.9%) 
 09/10 1054 (12.6%) 189 (11.6%) 865 (12.9%) 
 10/11 1135 (13.6%) 190 (11.7%) 945 (14.0%) 
 11/12 1089 (13.0%) 159 (9.8%) 930 (13.8%) 
 12/13 250 (3.0%) 31 (1.9%) 219 (3.3%) 
Comorbidity    
Psychiatric comorbidities    
 Dementia 3904 (46.7%) 762 (46.8%) 3142 (46.7%) 
 Schizophrenia 4429 (53.0%) 827 (50.8%) 3602 (53.5%) 
 Mood disorder  2445 (29.3%) 426 (26.2%) 2019 (30.0%) 
 Alcohol or drug abuse 206 (2.5%) 31 (1.9%) 175 (2.6%) 
 Extrapyramidal symptoms 294 (3.5%) 48.0 (3.0%) 246 (3.7%) 
Charlson index    
 0 2367 (28.3%) 480 (29.5%) 1887 (28.0%) 
 1-2 3878 (46.4%) 747 (45.9%) 3131 (46.5%) 
 3-4 1405 (16.8%) 265 (16.3%) 1140 (16.9%) 
 ≥ 5 708 (8.47%) 137 (8.41%) 571 (8.49%) 
Level of care
 
   
 Level 1 131 (1.6%) 21 (1.3%) 110 (1.6%) 
 Level 2 3707 (44.4%) 724 (44.4%) 2983 (44.3%) 
 Level 3 2267 (27.1%) 425 (26.1%) 1842 (27.4%) 
 Level 4 2251 (26.9%) 459 (28.2%) 1792 (26.6%) 
AHFS drug categories, x̅   S  (median) 7.3 ± 4.3 (7.0) 6.9 ± 4.1 (7.0) 7.4 ± 4.3 (7.0) 
 0-3 1584 (19.0%) 350 (21.5%) 1234 (18.3%) 
 4-6 2322 (27.8%) 448 (27.5%) 1874 (27.8%) 
 ≥ 7 4452 (53.3%) 831 (51.0%) 3621 (53.8%) 
Behavioural    
MDS-CPS
 
   
 Minimally impaired (0-1) 1300 (15.6%) 289 (17.7%) 1011 (15.0%) 
 Moderately impaired (2-3) 4395 (52.6%) 878 (53.9%) 3517 (52.3%) 
 Severely impaired (4-6) 2142 (25.6%) 441 (27.1%) 1701 (25.3%) 
 Missing 521 (6.2%) 21 (1.3%) 500 (7.4%) 
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Table 4.1 Continued    
Variables 
Overall 
(N = 8358) 
APM 
Discontinued 
(N = 1629) 
APM  
Continued 
(N = 6729) 
Behavioural    
MDS-CBP
 
   
 None (0) 1323 (15.8%) 315 (19.3%) 1008 (15.0%) 
 Mild (1-4) 3071 (36.7%) 686 (42.1%) 2385 (35.4%) 
 Moderate (5-9) 2169 (26.0%) 422 (25.9%) 1747 (26.0%) 
 Severe (10-14) 890 (10.6%) 133 (8.2%) 757 (11.2%) 
 Extreme (≥ 15) 378 (4.5%) 50 (3.1%) 328 (4.9%) 
 Missing 527 (6.3%) 23 (1.4%) 504 (7.5%) 
Drug exposure    
Days to APM initiation    
 0-30 days after admission 4858 (58.1%) 868 (53.3%) 3990 (59.3%) 
 31-90 days after admission  1543 (18.5%) 295 (18.1%) 1248 (18.5%) 
 > 90 days after admission 1957 (23.4%) 466 (28.6%) 1491 (22.2%) 
Last APM dispensation before LTCF admission    
 None in previous year 4235 (50.7%) 901 (55.3%) 3334 (49.5%) 
 > 30 days 1167 (14.0%) 193 (11.8%) 974 (14.5%) 
 ≤ 30 days 2956 (35.4%) 535 (32.8%) 2421 (36.0%) 
Last antidepressant dispensation before LTCF admission   
 None in previous year 5537 (66.2%) 1116 (68.5%) 4421 (65.7%) 
 > 30 days 1150 (13.8%) 200 (12.3%) 950 (14.1%) 
 ≤ 30 days 1671 (20.0%) 313 (19.2%) 1358 (20.2%) 
Last benzodiazepine dispensation before LTCF admission   
 None in previous year 6191 (74.1%) 1261 (77.4%) 4930 (73.3%) 
 > 30 days 1096 (13.1%) 188 (11.5%) 908 (13.5%) 
 ≤ 30 days 1071 (12.8%) 180 (11.0%) 891 (13.2%) 
Last anticholinergic dispensation before LTCF admission   
 None in previous year 7345 (87.9%) 1487 (91.3%) 5858 (87.1%) 
 > 30 days 603 (7.2%) 84 (5.2%) 519 (7.7%) 
 ≤ 30 days 410 (4.9%) 58 (3.6%) 352 (5.2%) 
Last cholinergic dispensation before LTCF admission   
 None in previous year 7401 (88.5%) 1407 (86.4%) 5994 (89.1%) 
 > 30 days 628 (7.51%) 149 (9.2%) 479 (7.1%) 
 ≤ 30 days 329 (3.9%) 73 (4.5%) 256 (3.80%) 
Health care utilization    
No transfer to new LTCF 5393 (64.5%) 1065 (65.4%) 4328 (64.3%) 
No hospitalization prior to LTCF admission 2529 (30.3%) 522 (32.0%) 2007 (29.8%) 
No hospitalization after LTCF admission 4870 (58.3%) 868 (53.3%) 4002 (59.5%) 
Abbreviations – AHFS: American hospital formulary system, APM: antipsychotic medication, MDS-CBP: 
minimum dataset challenging behaviour profile, MDS-CPS: minimum dataset cognitive performance scale, x̅   S : 
mean ± standard deviation.  
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Table 4.2 1LTCF characteristics of the study cohort. 
Variables 
Overall 
(N = 8358) 
APM 
Discontinued 
(N = 1629) 
APM  
Continued 
(N = 6729) 
 
n (%) n (%) n (%) 
Facility license status    
 Non-licensed 468 (5.6%) 51 (3.2%) 417 (6.20%) 
 Licensed 7889 (94.4%) 1578 (96.9%) 6311 (93.8%) 
Facility affiliation    
 Amalgamate (public) 4728 (56.6%) 897 (55.1%) 3831 (56.9%) 
 Affiliate (private, non-profit) 2686 (32.1%) 560 (34.4%) 2126 (31.6%) 
 Contract (private, for profit) 943 (11.3%) 172 (10.6%) 771 (11.5%) 
Facility type    
 Health centre 24 (0.3%) < 6
a ≥ 6a 
 Hospital 467 (5.6%) ≥ 6a ≥ 6a 
 Special care home 7508 (89.8%) 1499 (92.0%) 6009 (89.3%) 
 Integrated facility 358 (4.3%) 76 (4.67%) 282 (4.2%) 
Facility location    
 Other Health Region 4621 (55.3%) 900 (55.2%) 3721 (55.3%) 
 Regina Qu’Appelle Health Region 1570 (18.8%) 290 (17.8%) 1280 (19.0%) 
 Saskatoon Health Region 2166 (25.9%) 439 (26.9%) 1727 (25.7%) 
Facility size    
 Small (1-35 beds) 1728 (20.7%) 310 (19.0%) 1418 (21.1%) 
 Medium (36-100 beds) 3308 (39.6%) 689 (42.3%) 2619 (38.9%) 
 Large (> 100 beds) 2787 (33.3%) 574 (35.2%) 2213 (32.9%) 
 Missing 535 (6.4%) 56 (3.4%) 479 (7.1%) 
Abbreviations – APM: antipsychotic medication, LTCF: long-term care facility, x̅   S : mean ± standard deviation.  
Notes – a: frequency counts indicated by < 6 and ≥ 6 are are suppressed to protect privacy. 
 
4.2 APM utilization and discontinuation 
 
Utilization of APMs by the study cohort was characterized by dispensation count, time 
between subsequent dispensations, the type of APM first dispensed, and if a switch in APM 
occurred (Table 4.3).  A quarter (24.5%) of the cohort members received more than 25 APM 
dispensations, and another 26.5% received 10 to 25 dispensations during the observation period.  
A few cohort members (11.8%) received only a single APM dispensation (Table 4.3).  Generally, 
dispensation of APMs occurred regularly, with 73.9% of the study cohort members having less 
than 70 days between any two APM dispensations.  Relatively few members of the cohort 
(2.4%) had a gap of more than a year between two dispensations.  The first type of APM 
dispensed was primarily risperidone (58.9%) or quetiapine (28.9%).  Most residents (73.7%) did 
not switch APMs during the observation period. 
 
 
 28 
 
 
Table 4.3 1Antipsychotic medication utilization characteristics of among the study cohort. 
 
Overall 
(N = 8358) 
n (%) 
APM Discontinued 
(N = 1629) 
n (%) 
APM Continued 
(N = 6729) 
n (%) 
Dispensation count    
 1 APM dispensation 989 (11.8%) 341 (20.9%) 648 (9.6%) 
 2-5 APM dispensations 2102 (25.1%) 451 (27.7%) 1651 (24.5%) 
 6-9 APM dispensations 1012 (12.1%) 211 (13.0%) 801 (11.9%) 
 10-25 APM dispensations 2211 (26.5%) 361 (22.2%) 1850 (27.5%) 
 > 25 APM dispensations 2044 (24.5%) 265 (16.3%) 1779 (26.4%) 
Largest gap between APM dispensations
 
   
 ≤ 35 days 2663 (31.9%) 452 (27.7%) 2211 (32.9%) 
 36-70 days 3512 (42.0%) 562 (34.5%) 2950 (43.8%) 
 71-105 days 463 (5.5%) 84 (5.2%) 379 (5.6%) 
 106-365 days 528 (6.3%) 135 (8.3%) 393 (5.8%) 
 > 1 year 203 (2.4%) 55 (3.4%) 148 (2.2%) 
 Missing
a
 989 (11.8%) 341 (20.9%) 648 (9.6%) 
Index APM dispensation    
 Risperidone 4919 (58.9%) 995 (61.1%) 3924 (58.3%) 
 Quetiapine 2418 (28.9%) 413 (25.4%) 2005 (29.8%) 
 Haloperidol 578 (6.9%) 139 (8.5%) 439 (6.5%) 
 Other 443 (5.3%) 82 (5.0%) 361 (5.4%) 
Switched APM    
 No
 
6156 (73.7%) 1136 (69.7%) 5020 (74.6%) 
 Yes 1213 (14.5%) 152 (9.3%) 1061 (15.8%) 
 Missing
a
 989 (11.8%) 341 (20.9%) 648 (9.6%) 
Abbreviations – APM: antipsychotic medication.  Notes – a: Only 1 APM dispensation. 
 
Variation in APM discontinuation rates were examined across facilities.  The proportion 
of discontinuers varied from less than 5% to more than 30%, with most facilities ranging 
between 10% and 30% (Figure 4.2).  Only 204 residents were in facilities with discontinuation 
rates between 0%-5%, and none of these facilities had more than 25 residents.  Some facilities 
had discontinuation rates of 30% or more; a total of 599 individuals were located in these 
facilities .  These residents primarily resided in facilities with discontinuation rates between 
30%-40%, but a few facilities had very high discontinuation rates of close to 100%.  The average 
of facility specific discontinuations was calculated for facilities according to affiliation, health 
region, and size.  Discontinuation varied from 17.4% (95% CI: 15.1%-19.7%) among 
amalgamate facilities to 20.4% (95% CI: 16.9%-24.0%) among affiliates (Figure 4.3).  The 
facilities in the Regina Qu’Appelle health region had the lowest discontinuation (15.2%, 95% CI: 
10.9%-19.5%), while discontinuation was highest in Saskatoon facilities (Figure 4.4).  Smaller 
LTCFs had the lowest discontinuation (18.2%, 95% CI: 16.0%-20.3%) and medium facilities had 
the highest discontinuation (22.5%, 95% CI: 19.2%-25.7%) (Figure 4.5).  LTCFs with a missing 
facility size had low discontinuation (7.5%, 95% CI: 0.9%-14.0%). 
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Figure 4.2 1Histogram of facility specific discontinuation percentages (n = 206). 
 
Figure 4.3 1Facility specific discontinuation percentages averaged by facility affiliation (n = 206). 
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Figure 4.4 1Facility specific discontinuation percentages averaged by facility health region (n = 206). 
 
Figure 4.5 1Facility specific discontinuation percentages averaged by facility size (n = 206). 
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The EOR for each resident was calculated and divided into quintiles.  More than 60% of 
the cohort had an EOR greater than 365 days (Table 4.4).  Discontinuation was low (2%) for 
cohort members with an EOR in the first quintile (1-124 days), but higher (32.6%) for cohort 
members in the fifth EOR quintile (Table 4.4).  This trend of discontinuation being concentrated 
among study cohort members with long EORs was observed when the analysis was stratified by 
the key study variables of dementia diagnosis, schizophrenia diagnosis, transfer to a new LTCF, 
APM exposure, and days to APM initiation.  Discontinuation increased from 17.9% to 19.1% 
and 23.8% among residents initiating APMs within 0-30 days, 31-90 days and > 90 days of 
LTCF admission. 
Analysis of the distribution of APM discontinuations by follow-up time quintiles showed 
that the greatest proportion of discontinuations (27.2%) occurred within 55 days of the first APM 
dispensation (Table 4.5).  The percentage of discontinuations decreased slightly among residents 
that were within the second (56-169 days) or third (170-447 days) time to event quintiles.  
Discontinuations occurred the least frequently among the cohort members within the longest 
times to event quintiles.  Only 15.6% and 16.5% of the cohort members that discontinued APMs 
were in the fourth (448-901 days) and fifth (902-3265 days) time to event quintiles, respectively.  
The percentage of cohort members that were right censored due to an alternative event occurring 
before APM discontinuation was relatively constant across time to event quintiles, ranging 
between 18.1% and 21.0%.  Stratification of the results by dementia diagnosis, schizophrenia 
diagnosis, transfer to a new LTCF, last APM dispensation, and days to APM initiation revealed a 
similar trend of the discontinuations occurring most frequently within the first time to event 
quintile.  Stratification indicates that a greater percentage of discontinuations occurred in the first 
time to event quintile (1-55 days) for residents that did not have a diagnosis code for dementia, 
or schizophrenia.  Similarly, cohort members that transferred to a new LTCF, had no prior APM 
dispensations, or initiated APMs > 90 days after admission to a LTCF had higher percentage of 
APM discontinuations within the first time to event quintile. 
 
  
 
 
Table 4.4 1Characteristics of cohort members who discontinued APMs, stratified by duration of EOR quintile 
  EOR day quintiles, n (%)
a 
 
  Q1 1-124 days Q2 125-395 days Q3 396-754 days Q4 755-1290 days Q5 1291-3265 days Cohort Total 
Overall 
Discontinued APM 33 (2.0%) 271 (16.1%) 363 (21.7%) 417 (25.0%) 545 (32.6%) 1629 (19.5%) 
Total 1668 1680 1673 1665 1672 8358 
Dementia        
No 
Discontinued APM 19 (2.2%) 135 (15.8%) 196 (21.5%) 230 (25.3%) 287 (30.8%) 867 (19.5%) 
Total 850 853 911 908 932 4454 
Yes 
Discontinued APM 14 (1.7%) 136 (16.4%) 167 (21.9%) 187 (24.7%) 258 (34.9%) 762 (19.5%) 
Total 818 827 762 757 740 3904 
Schizophrenia       
No 
Discontinued APM 23 (2.8%) 137 (17.5%) 179 (23.7%) 205 (26.6%) 258 (32.4%) 802 (20.4%) 
Total 820 785 756 771 797 3929 
Yes 
Discontinued APM 10 (1.2%) 134 (15.0%) 184 (20.1%) 212 (23.7%) 287 (32.8%) 827 (18.7%) 
Total 848 895 917 894 875 4429 
Transfer to new LTCF       
No 
Discontinued APM 21 (2.1%) 170 (16.2%) 218 (20.3%) 274 (25.0%) 382 (33.1%) 1065 (19.7%) 
Total 1019 1051 1075 1094 1154 5393 
Yes 
Discontinued APM 12 (1.8%) 101 (16.1%) 145 (24.2%) 143 (25.0%) 163 (31.5%) 564 (19.0%) 
Total 649 629 598 571 518 2965 
Last APM exposure before LTCF admission      
None in  
previous year 
Discontinued APM 23 (2.9%) 136 (16.6%) 209 (24.5%) 236 (26.5%) 297 (33.6%) 901 (21.3%) 
Total 786 820 854 891 884 4235 
> 30 days 
Discontinued APM < 6
b 
 6b 39 (18.9%) 49 (22.7%) 67 (29.9%) 193 (16.5%) 
Total 271 250 206 216 224 1167 
≤ 30 days 
Discontinued APM  6b  6b 115 (18.8%) 132 (23.7%) 181 (32.1%) 535 (18.1%) 
Total 611 610 613 558 564 2956 
Days to APM initiation after LTCF admission      
0-30 days 
Discontinued APM 27 (2.1%) 189 (18.6%) 197 (21.1%) 197 (24.2%) 258 (32.4%) 868 (17.9%) 
Total 1297 1017 935 813 796 4858 
31-90 days 
Discontinued APM 6 (1.7%) 63 (15.8%) 69 (22.8%) 86 (32.1%) 71 (31.8%) 295 (19.1%) 
Total 349 400 303 268 223 1543 
> 90 days 
Discontinued APM 0 (0.0%) 19 (7.2%) 97 (22.3%) 134 (22.9%) 216 (33.1%) 466 (23.8%) 
Total 22 263 435 584 653 1957 
Abbreviations – APM: antipsychotic medication, EOR: episode of residence, LTCF: long-term care facility.  Notes – a: proportions are calculated within each 
EOR quintile by dividing the discontinued APM count by the total count. b: frequency counts indicated by < 6 and ≥ 6 are are suppressed to protect privacy. 
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Table 4.5 1Frequencies and percentages of cohort members that continued or discontinued APMs, stratified by time to event quintiles. 
  Time to event quintile, n (%)
a
  
  Q1 1-55 days Q2 56-169 days Q3 170-447 days Q4 448-901 days Q5 902-3265 days Cohort Total 
Overall 
Discontinued APM 443 (27.2%) 331 (20.3%) 332 (20.4%) 254 (15.6%) 269 (16.5%) 1629 
Continued APM 1221 (18.1%) 1349 (20.0%) 1341 (19.9%) 1416 (21.0%) 1402 (20.8%) 6729 
Dementia        
No 
Discontinued APM 274 (31.6%) 163 (18.8%) 159 (18.3%) 151 (17.4%) 120 (13.8%) 867 
Continued APM 678 (18.9%) 682 (19.0%) 742 (20.7%) 739 (20.6%) 746 (20.8%) 3587 
Yes 
Discontinued APM 169 (22.2%) 168 (22.0%) 173 (22.7%) 103 (13.5%) 149 (19.6%) 762 
Continued APM 543 (17.3%) 667 (21.2%) 599 (19.1%) 677 (21.5%) 656 (20.9%) 3142 
Schizophrenia       
No 
Discontinued APM 252 (31.4%) 171 (21.3%) 157 (19.6%) 108 (13.5%) 114 (14.2%) 802 
Continued APM 663 (21.2%) 661 (21.1%) 609 (19.5%) 619 (19.8%) 575 (18.4%) 3127 
Yes 
Discontinued APM 191 (23.1%) 160 (19.3%) 175 (21.2%) 146 (17.7%) 155 (18.7%) 827 
Continued APM 558 (15.5%) 688 (19.1%) 732 (20.3%) 797 (22.1%) 827 (23.0%) 3602 
Transfer to new LTCF       
No 
Discontinued APM 259 (24.3%) 211 (19.8%) 234 (22.0%) 166 (15.6%) 195 (18.3%) 1065 
Continued APM 746 (17.2%) 844 (19.5%) 872 (20.1%) 937 (21.6%) 929 (21.5%) 4328 
Yes 
Discontinued APM 184 (32.6%) 120 (21.3%) 98 (17.4%) 88 (15.6%) 74 (13.1%) 564 
Continued APM 475 (19.8%) 505 (21.0%) 469 (19.5%) 479 (20.0%) 473 (19.7%) 2401 
Last APM exposure before LTCF admission      
None in  
previous year 
Discontinued APM 320 (35.5%) 184 (20.4%) 168 (18.6%) 125 (13.9%) 104 (11.5%) 901 
Continued APM 732 (22.0%) 686 (20.6%) 700 (21.0%) 662 (19.9%) 554 (16.6%) 3334 
> 30 days 
Discontinued APM 37 (19.2%) 46 (23.8%) 40 (20.7%) 32 (16.6%) 38 (19.7%) 193 
Continued APM 171 (17.6%) 205 (21.0%) 173 (17.8%) 205 (21.0%) 220 (22.6%) 974 
≤ 30 days 
Discontinued APM 86 (16.1%) 101 (18.9%) 124 (23.2%) 97 (18.1%) 127 (23.7%) 535 
Continued APM 318 (13.1%) 458 (18.9%) 468 (19.3%) 549 (22.7%) 628 (25.9%) 2421 
Days to APM initiation after LTCF admission      
0-30 days 
Discontinued APM 190 (21.9%) 189 (21.8%) 182 (21.0%) 136 (15.7%) 171 (19.7%) 868 
Continued APM 654 (16.4%) 880 (22.1%) 723 (18.1%) 831 (20.8%) 902 (22.6%) 3990 
31-90 days 
Discontinued APM 82 (27.8%) 56 (19.0%) 54 (18.3%) 61 (20.7%) 42 (14.2%) 295 
Continued APM 283 (22.7%) 233 (18.7%) 236 (18.9%) 244 (19.6%) 252 (20.2%) 1248 
> 90 days 
Discontinued APM 171 (36.7%) 86 (18.5%) 96 (20.6%) 57 (12.2%) 56 (12.0%) 466 
Continued APM 284 (19.0%) 236 (15.8%) 382 (25.6%) 341 (22.9%) 248 (16.6%) 1491 
Abbreviations – APM: antipsychotic medication, LTCF: long-term care facility.  Notes – a:  proportions calculated by dividing the quintile 
discontinued APM count by the cohort total discontinued APM count, with an analogous calculation used for residents that continued APMs. 
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The primary definition of APM discontinuation specified that a 35 day period of non-
exposed follow-up time must be observed with no alternate events occurring within that period.  
Two alternate definitions that shortened the non-exposure period to 0 days or lengthened the 
non-exposure period to 70 days were used in a sensitivity analysis.  APM discontinuation 
frequencies were 2298 (27.5%), and 1424 (17.0%) for the shorter non-exposure, and longer non-
exposure definitions, respectively (Table 4.6).  Using the primary definition of APM 
discontinuation the time to event, on average, was 1.40 years (SD = 1.59), while the median was 
0.80 years (9.6 months) (Table 4.6).  These values were nearly identical to the results for both 
alternate APM discontinuation definitions.  The KM non-parametric estimator of the median 
time to event was 6.5 years under the primary definition of APM discontinuation (Figure 4.2).  
Shortening the definition of the non-exposure period shortened the median KM estimate of time 
to event to 4.1 years.  The longer non-exposure period definition of discontinuation increased the 
KM estimate of the median time to event to be greater than 6.5 years.
1
 
 
 
Table 4.6 1Discontinuation counts, crude time to event, and Kaplan-Meier estimates of time to event for three 
definitions of APM discontinuation. 
 APM discontinuation definitions 
 
35 days of non-
exposure time  
after APM 
discontinuation
a 
0 days of non-
exposure time  
after APM 
discontinuation
b 
70 days of non-
exposure time  
after APM 
discontinuation
b 
APM discontinued, n (%) 1629 (19.5%) 2298 (27.5%) 1424 (17.0%) 
Time to event (years), mean ± SE (median)    
 Overall 1.40 ± 1.59 (0.80) 1.40 ± 1.59 (0.80) 1.41 ± 1.59 (0.80) 
 Discontinued 1.14 ± 1.36 (0.55) 1.20 ± 1.39 (*) 1.13 ± 1.37 (0.56) 
 Continued 1.47 ± 1.63 (0.88) 1.48 ± 1.65 (0.89) 1.46 ± 1.62 (0.88) 
Kaplan-Meier estimates of time to event (years)    
 Median (95% CI) 6.5 (5.7 – NE) 4.1 (4.0 – 4.3) * 
 Mean ± SE 5.27 ± 0.07 4.40 ± 0.06 5.56 ± 0.07 
Abbreviations – APM: antipsychotic medication, SE: standard error, 95% CI: 95% confidence interval.  Notes – a: 
primary definition of APM discontinuation. b: definitions of APM discontinuation  used for sensitivity analyses.  
Symbols – *, cell size ≤ 5 and suppressed to protect privacy; NE, not estimated. 
 
 
                                                          
1
 Cannot report the exact KM median time to event for the 70 day non-exposure period because the number of 
residents with this time to event is < 6, resulting in the suppression of this value for privacy. 
 35 
 
 
 
Figure 4.6 1Kaplan-Meier survival probability for three definitions of APM discontinuation that varied the length of 
the non-exposure period after the last APM dispensation. 
4.3 Cox regression model results 
 
Clustering of individuals within LTCFs could lead to violation of the independence 
assumption, but the analysis indicates minimal clustering.  The null model (i.e., no predictors) 
had a covariance (SD) of 0.064 (0.020) and was significant (p = 0.0003).  The addition of the 
clustering analysis to the fully adjusted model with covariate time interactions increased the 
covariance (SD) to 0.111 (0.028), which was also significant (p < 0.0001). 
Model selection information and fit statistics are reported in Table 4.7.  The inclusion of 
demographic variables (model 2) reduced the AIC when compared to the null model (model 1).  
The LRT for these nested models was statistically significant (p < 0.0001).  To examine the 
contribution of the remaining sets of variables that measured comorbidity, behaviour, drug 
exposures, health care utilization, and LTCF characteristics, each variable group was 
individually added to the baseline (i.e., demographic) model.  The addition of variables 
measuring comorbidity (model 3), behavioural (model 4), drug exposure (model 5), and health 
care utilization (model 6) resulted in a reduced AIC when compared to model 2.   The LRT 
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statistic for each of these nested models was statistically significant (p-value ranged from 0.009 
to < 0.0001).  The variable group containing LTCF characteristics (model 7) resulted in a non-
significant LRT (p = 0.2477).   
The groups of explanatory variables were also added sequentially to assess fit as the 
complexity of the models increased (models 1, 2, 3, 8, 9, 10, 11).  The AIC decreased with 
sequential addition of variables describing demographic characteristics, comorbidity, behavioural 
traits, drug exposures, health care utilization measures, and LTCF features.  All LRTs were 
statistically significant, except for the LRT associated with the LTCF variables (model 11).  
Additionally, it should be noted that the AIC of the model including drug exposures (model 9) 
decreased by only a small amount with the addition of health care utilization (model 10) and 
LTCF variables (model 11).    Finally, the inclusion of covariate-time interactions to adjust for 
non-proportional hazards resulted in a large decrease in the AIC, and a statistically significant 
LRT (p < 0.0001; model 12).   The violation of the proportional hazards assumption is 
demonstrated by crossing KM survival curves for sex (Figure 4.7) and dementia (Figure 4.8).  
The proportional hazards assumption was also violated for prior APM exposure, MDS-CPS, 
hospitalization before LTCF admission, and facility location (Appendix E).  
The SBC increased for most models, which indicates poorer fit after penalizing for the 
number of included variables.  It decreased only after adding covariate-time interactions (model 
12).  As for the c-statistic, the value for the fully adjusted model (i.e., model 11) indicated good 
discrimination, but the value was slightly lower than for less complex models. 
The HRs for all covariates are reported for univariate, partially adjusted, and fully 
adjusted main effects models, as well as for the extended Cox model with covariate-time 
interactions (Table 4.8).  For variables that interact with time the HR is reported over time (Table 
4.9). 
The demographic variables of sex and index year had a statistically significant 
association with APM discontinuation.  The HR for the index fiscal year decreased between 
2007/08 and 2011/12 from 0.80 (95% CI: 0.66-0.97) to 0.58 (95% CI: 0.47-0.71).  The effect of 
sex was not proportional over time, and at the start of follow-up the risk of APM discontinuation 
was 2.66 (95% CI: 2.26-3.13) times greater for females than males (Table 4.9).  Over two years 
of follow-up the HR decreased to 0.92 (95% CI: 0.82-1.04). 
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Table 4.7 1Model fit statistics 
Model description df AIC SBC 
c-statistic 
(95% CI) 
Model 1: No predictors 0 25288 25288 - 
Model 2: Demographic 11 25251 25310 0.92 (0.89-0.95) 
Model 3: Demographic + comorbidity 24 25218 25347 0.89 (0.86-0.92) 
Model 4: Demographic + behavioural 17 25205 25296 0.89 (0.86-0.92) 
Model 5: Demographic + drug exposure 23 25176 25299 0.88 (0.84-0.91) 
Model 6: Demographic + health care utilization 14 25246 25321 0.91 (0.88-0.94) 
Model 7: Demographic + LTCF 17 25256 25346 0.92 (0.89-0.94) 
Model 8: Demographic + comorbidity + behavioural 30 25179 25339 0.87 (0.84-0.90) 
Model 9: Demographic + comorbidity + behavioural + drug 
exposure 
42 25121 25345 0.85 (0.81-0.88) 
Model 10: Demographic + comorbidity + behavioural + 
drug exposure + health care utilization 
45 25118 25358 0.84 (0.81-0.88) 
Model 11: Demographic + comorbidity + behavioural + 
drug exposure + health care utilization + LTCF 
51 25120 25393 0.84 (0.80-0.87) 
Model 12: Demographic + comorbidity + behavioural + 
drug exposure + health care utilization + LTCF + covariate-
time interactions 
60 22249 22569 - 
Abbreviations – AIC: Akaike Information Criterion, df: degrees of freedom, LTCF: long-term care facility, SBC: 
Schwartz-Bayesian Criterion.  Notes – An estimate of the survival function cannot be calculated for models with 
time interactions. 
 
Among comorbidity variables, only dementia had a significant effect on the hazard of 
APM discontinuation.  This effect varied over time, and at the start of follow-up residents with 
dementia were 0.86 (95% CI: 0.73-1.01) times as likely to discontinue an APM as those without 
dementia (Table 4.9).  After two years no difference in APM discontinuation (HR [95% CI]: 1.01 
[0.89-1.15]) was present between cohort members with and without dementia.   
The MDS-CPS had a statistically significant association with APM discontinuation that 
varied over time, while an inconsistent association with the outcome was detected for the MDS-
CBP variable.  When the first APM was dispensed residents with moderate cognitive impairment 
were 4.20 (95% CI: 3.29-5.36) times more likely to discontinue APMs than those with mild 
cognitive impairment.  A similar HR (HR [95% CI]: 4.07 [3.09-5.38]) was observed for residents 
with severe cognitive impairment.  After two years of follow-up APM discontinuation was no 
different between residents with minimal, moderate, or severe cognitive impairment.  
Considering MDS-CBP scores, residents with mild challenging behaviours were more likely to 
discontinue (HR [95% CI]: 1.16 [1.00-1.35]), while those with severe challenging behaviours 
were less likely to discontinue APMs (HR [95% CI]: 0.76 [0.61-0.95]), than residents with no 
challenging behaviours.  However, the hazard of APM discontinuation did not differ between 
moderate or extreme MDS-CBP scores, relative to no challenging behaviours. 
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Figure 4.7 1Kaplan-Meier survival probability by resident sex. 
 
Figure 4.8 1Kaplan-Meier survival probability by dementia diagnosis. 
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Table 4.8 1Univariate, partially adjusted, and fully adjusted Cox proportional hazards regression models of APM 
discontinuation. 
Explanatory variables
a 
Univariate model 
Partially adjusted 
model
b
 
Fully adjusted 
model
c 
Covariate-time  
interaction model
 d 
Demographic HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) 
Age     
 75-84 1.18 (0.98-1.41) 1.18 (0.99-1.41) 1.10 (0.91-1.31) 1.19 (0.98-1.44) 
 85-94 1.53 (1.29-1.82)* 1.56 (1.31-1.86)* 1.38 (1.15-1.65)* 1.34 (1.11-1.63)* 
 ≥ 95 1.72 (1.32-2.24)* 1.76 (1.34-2.29)* 1.53 (1.16-2.01)* 1.17 (0.89-1.55) 
 65-74 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Sex     
 Female 1.00 (0.90-1.11) 0.93 (0.83-1.03) 0.93 (0.83-1.04) * 
 Male 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Index fiscal year     
 04/05 0.73 (0.59-0.89)* 0.72 (0.58-0.88)* 0.77 (0.63-0.95)* 0.98 (0.80-1.21) 
 05/06 0.97 (0.81-1.17) 0.97 (0.80-1.16) 1.02 (0.85-1.23) 1.00 (0.83-1.21) 
 06/07 0.94 (0.78-1.13) 0.94 (0.78-1.13) 0.96 (0.80-1.15) 0.87 (0.72-1.05) 
 07/08 0.82 (0.68-0.99)* 0.81 (0.67-0.98)* 0.84 (0.69-1.01) 0.80 (0.66-0.97)* 
 09/10 0.89 (0.73-1.08) 0.88 (0.72-1.06) 0.89 (0.73-1.08) 0.76 (0.63-0.93)* 
 10/11 0.95 (0.78-1.15) 0.93 (0.77-1.13) 0.94 (0.77-1.14) 0.75 (0.61-0.91)* 
 11/12 0.99 (0.81-1.22) 0.98 (0.79-1.20) 0.97 (0.79-1.19) 0.58 (0.47-0.71)* 
 12/13
 
- - - - 
 08/09 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Comorbidity     
Dementia      
 Yes 0.97 (0.88-1.07) 1.05 (0.94-1.16) 1.03 (0.92-1.15) - 
 No 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Schizophrenia     
 Yes 0.78 (0.71-0.86)* 0.82 (0.74-0.91)* 0.88 (0.79-0.98)* 1.01 (0.90-1.13) 
 No 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Mood disorder       
 Yes 0.75 (0.67-0.84)* 0.79 (0.70-0.89)* 0.84 (0.74-0.95)* 0.94 (0.83-1.07) 
 No 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Alcohol or drug abuse     
 Yes 0.73 (0.51-1.05) 0.87 (0.60-1.26) 0.84 (0.58-1.22) 0.94 (0.65-1.37) 
 No 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Extrapyramidal symptoms      
 Yes 0.74 (0.56-0.99)* 0.81 (0.60-1.08) 0.87 (0.65-1.17) 1.02 (0.76-1.37) 
 No 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Charlson index      
 1-2 0.94 (0.83-1.06) 0.94 (0.83-1.06) 0.94 (0.83-1.05) 0.94 (0.83-1.06) 
 3-4 1.01 (0.86-1.17) 0.99 (0.85-1.16) 0.98 (0.84-1.15) 0.99 (0.84-1.15) 
 ≥ 5 1.00 (0.82-1.21) 1.00 (0.82-1.21) 1.00 (0.82-1.21) 0.95 (0.78-1.16) 
 0 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Level of care       
 Level 2 1.56 (1.00-2.44)* 1.61 (1.03-2.52)* 1.74 (1.10-2.76)* 1.46 (0.91-2.33) 
 Level 3 1.43 (0.91-2.23) 1.48 (0.94-2.33) 1.70 (1.07-2.71)* 1.32 (0.82-2.11) 
 Level 4 1.85 (1.18-2.89)* 1.83 (1.17-2.87)* 2.03 (1.27-3.24)* 1.65 (1.02-2.65)* 
 Level 1 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
AHFS drug category      
 4-6 0.89 (0.77-1.03) 0.89 (0.77-1.03) 0.94 (0.81-1.09) 0.88 (0.75-1.02) 
 ≥ 7 0.94 (0.83-1.07) 0.97 (0.85-1.11) 1.11 (0.96-1.29) 0.90 (0.77-1.04) 
 0-3 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
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Table 4.8  Continued     
Explanatory variables
a 
Univariate models 
Partially adjusted 
models
b
 
Fully adjusted 
models
c 
Covariate time  
interaction models
 d 
MDS-CPS     
 Moderately impaired (2-3) 0.81 (0.71-0.93)* 0.87 (0.76-1.01) 0.87 (0.75-1.01) * 
 Severely impaired (4-6) 0.91 (0.78-1.05) 1.09 (0.93-1.28) 1.11 (0.93-1.32) * 
 Minimally impaired (0-1) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
MDS-CBP     
 Mild (1-4) 0.95 (0.82-1.08) 0.96 (0.83-1.10) 1.02 (0.88-1.17) 1.16 (1.00-1.35)* 
 Moderate (5-9) 0.80 (0.69-0.92)* 0.80 (0.68-0.93)* 0.86 (0.73-1.00) 0.95 (0.80-1.12) 
 Severe (10-14) 0.58 (0.47-0.71)* 0.58 (0.47-0.72)* 0.64 (0.51-0.79)* 0.76 (0.61-0.95)* 
 Extreme (≥ 15) 0.54 (0.40-0.72)* 0.54 (0.40-0.73)* 0.59 (0.43-0.81)* 0.73 (0.53-1.01) 
 None (0) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Drug exposure     
Days to APM initiation after LTCF admission    
 31-90 days 1.17 (1.03-1.34)* 1.06 (0.92-1.21) 1.01 (0.88-1.17) 0.95 (0.82-1.10) 
 > 90 days 1.54 (1.37-1.73)* 1.23 (1.08-1.41)* 1.16 (1.01-1.33)* 1.07 (0.93-1.24) 
 0-30 days 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Last APM dispensation before LTCF admission    
 ≤ 30 days 0.64 (0.57-0.71)* 0.74 (0.65-0.85)* 0.75 (0.65-0.86)* * 
 > 30 days 0.63 (0.54-0.74)* 0.72 (0.61-0.85)* 0.72 (0.60-0.85)* - 
 None in previous year 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Last antidepressant dispensation before LTCF admission   
 ≤ 30 days 0.81 (0.72-0.93)* 0.94 (0.82-1.07) 0.94 (0.82-1.09) 1.12 (0.97-1.29) 
 > 30 days 0.92 (0.79-1.08) 1.03 (0.88-1.21) 1.03 (0.88-1.22) 1.05 (0.89-1.23) 
 None in previous year 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Last benzodiazepine dispensation before LTCF admission   
 ≤ 30 days 0.73 (0.62-0.85)* 0.80 (0.68-0.94)* 0.80 (0.68-0.95)* 0.79 (0.66-0.93)* 
 > 30 days 0.77 (0.66-0.90)* 0.84 (0.72-0.99)* 0.86 (0.73-1.01) 0.88 (0.75-1.04) 
 None in previous year 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Last anticholinergic dispensation before LTCF admission   
 ≤ 30 days 0.75 (0.57-0.98)* 0.89 (0.68-1.16) 0.81 (0.62-1.07) 0.78 (0.60-1.03) 
 > 30 days 0.74 (0.59-0.93)* 0.86 (0.69-1.08) 0.79 (0.63-1.00)* 0.80 (0.63-1.01) 
 None in previous year 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Last cholinergic dispensation before LTCF 
admission 
   
 ≤ 30 days 1.07 (0.84-1.35) 1.14 (0.90-1.45) 1.22 (0.96-1.56) 1.31 (1.02-1.67)* 
 > 30 days 1.19 (1.00-1.41)* 1.28 (1.07-1.52)* 1.40 (1.16-1.67)* 1.38 (1.15-1.66)* 
 None in previous year 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Health care utilization     
Transfer to new LTCF     
 Yes 1.07 (0.96-1.19) 1.02 (0.91-1.14) 0.91 (0.81-1.02) 0.87 (0.77-0.98)* 
 No 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Hospitalization prior to LTCF admission    
 Yes 1.12 (1.00-1.24)* 1.11 (0.99-1.24) 1.10 (0.97-1.24) * 
 No 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Hospitalization after LTCF admission    
 Yes 1.12 (1.01-1.24)* 1.14 (1.03-1.26)* 1.13 (1.02-1.26)* 1.12 (1.01-1.24)* 
 No 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
LTCF     
Facility affiliation     
 Affiliate (private, non-profit) 1.04 (0.93-1.16) 1.03 (0.91-1.18) 1.09 (0.95-1.25) 1.16 (1.00-1.33)* 
 Contract (private, for profit) 1.07 (0.91-1.27) 1.12 (0.92-1.36) 1.09 (0.89-1.34) 0.96 (0.78-1.19) 
 Amalgamate (public) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
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Table 4.8  Continued     
Explanatory variables
a 
Univariate models 
Partially adjusted 
models
b
 
Fully adjusted 
models
c 
Covariate time  
interaction models
 d 
 Regina Qu'Appelle 0.94 (0.82-1.07) 0.92 (0.78-1.07) 0.98 (0.83-1.16) * 
 Saskatoon 1.08 (0.96-1.21) 1.04 (0.90-1.19) 1.10 (0.95-1.27) * 
 Other 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Facility size     
 Small (1-35 beds) 0.95 (0.82-1.09) 0.92 (0.79-1.07) 0.92 (0.79-1.07) 0.90 (0.77-1.06) 
 Medium (36-100 beds) 1.10 (0.98-1.23) 1.05 (0.93-1.19) 1.02 (0.90-1.15) 1.01 (0.89-1.14) 
 Large (> 100 beds) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Time interaction with     
 Sex N/A N/A N/A * 
 Dementia  N/A N/A N/A * 
 MDS-CPS N/A N/A N/A * 
 Last APM dispensation 
before LTCF admission 
N/A N/A N/A * 
 Hospitalization prior to 
LTCF admission 
N/A N/A N/A * 
 Facility location N/A N/A N/A * 
Abbreviations – AHFS: American hospital formulary system, APM: antipsychotic medication, HR (95% CI): 
Hazard ratio (95% confidence interval), LTCF: long-term care facility, MDS-CBP: minimum dataset challenging 
behaviour profile, MDS-CPS: minimum dataset cognitive performance scale, N/A: not applicable  Notes – a: 
Explanatory variables are grouped by concept, which is indicated by the bold-italicized terms.  b: Partially adjusted 
models include all group variables and demographic variables.  Therefore, the six partially adjusted models include 
the variable groups demographic, demographic + comorbidity, demographic + behavioural, demographic + drug 
exposure, demographic + health care utilization, and demographic + LTCF.  c: Fully adjusted models include all 
variables.  d: Covariate time interaction model is a fully adjusted model with the addition of time-covariate 
interactions.  Symbols - *, p < 0.05. 
 
 Exposure to APMs, benzodiazepines, and cholinergic agents were all found to have a 
statistically significant association with APM discontinuation (Tables 4.8 and 4.9).  Residents 
dispensed a benzodiazepine within 30 days of LTCF admission had a significantly lower risk 
(HR = 0.79, 95% CI: 0.66-0.93) of discontinuing APMs than cohort members without prior 
benzodiazepine exposure.  However, no difference existed between residents not dispensed a 
benzodiazepine and those that were dispensed one more than 30 days before LTCF admission.  
Cohort members that were dispensed a cholinergic agent were more likely to discontinue APMs, 
compared to those without a dispensation.  Residents dispensed a cholinergic agent within 30 
days (HR [95% CI]: 1.31 [1.02-1.67]), and more than 30 days (HR [95% CI]: 1.38 [1.15-1.66]), 
prior to LTCF admission were both more likely to discontinue APMs than residents without 
exposure to these agents.  At the start of follow-up residents dispensed an APM within 30 days 
of being admitted to a LTCF had a higher rate of APM discontinuation (HR [95% CI]: 1.43 
[1.20-170]) than residents with no APM exposure.  Within a year of follow-up no difference in 
APM discontinuation (HR [95% CI]: 1.02 [0.88-1.17]) was observed between groups of 
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residents, and by two years this effect was reversed (HR [95% CI]: 0.72 [0.62-0.84]).  Residents 
dispensed an APM more than 30 days prior to LTCF admission did not differ in APM 
discontinuations relative to those without APM exposure at the start of follow-up.  However, 
after two years these residents were also less likely to discontinue APMs (HR = 0.75, 95% CI 
0.61-0.90). 
 
Table 4.9 1Hazard ratios (HR) and 95% confidence intervals (95% CIs) for covariate-time interactions from 
extended Cox model. 
 Follow-up time 
(days) 
    
 0 days 90 days 180 days 365 days 730 days 
Variables HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) 
Sex       
 Female 2.66 (2.26-3.13) 2.34 (2.01-2.72) 2.05 (1.78-2.36) 1.57 (1.38-1.77) 0.92 (0.82-1.04) 
 Male  1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Dementia      
 Yes 0.86 (0.73-1.01) 0.88 (0.75-1.02) 0.89 (0.78-1.03) 0.93 (0.83-1.05) 1.01 (0.89-1.15) 
 No 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
MDS-CPS      
 Moderately impaired (2-3) 4.20 (3.29-5.36) 3.42 (2.72-4.30) 2.79 (2.25-3.45) 1.83 (1.52-2.21) 0.80 (0.68-0.95) 
 Severely impaired (4-6) 4.07 (3.09-5.38) 3.41 (2.63-4.41) 2.85 (2.24-3.63) 1.98 (1.60-2.44) 0.96 (0.79-1.17) 
 Minimally impaired (0-1) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Last APM dispensation before LTCF admission    
 ≤ 30 days 1.43 (1.20-1.70) 1.31 (1.11-1.55) 1.21 (1.03-1.41) 1.02 (0.88-1.17) 0.72 (0.62-0.84) 
 > 30 days 1.18 (0.93-1.50) 1.11 (0.89-1.39) 1.05 (0.86-1.29) 0.94 (0.78-1.12) 0.75 (0.61-0.90) 
 None in previous year 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Hospitalization prior to LTCF admission     
 Yes 4.80 (3.92-5.88) 3.89 (3.23-4.70) 3.16 (2.65-3.76) 2.05 (1.76-2.39) 0.88 (0.76-1.01) 
 No 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Facility Health Region      
 Regina Qu'Appelle 1.26 (1.01-1.57) 1.21 (0.99-1.49) 1.17 (0.97-1.41) 1.08 (0.91-1.28) 0.93 (0.78-1.11) 
 Saskatoon 1.59 (1.30-1.95) 1.48 (1.23-1.78) 1.37 (1.16-1.63) 1.18 (1.01-1.38) 0.87 (0.74-1.04) 
 Other 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Abbreviations – APM: antipsychotic medication, HR (95% CI): Hazard ratio (95% confidence interval), LTCF: long-
term care facility, MDS-CPS: minimum dataset cognitive performance scale. 
 
Transfer to a new LTCF, and hospitalization before or after LTCF admission 
significantly impacted APM discontinuation.  Cohort members that transferred to a new LTCF 
were less likely to discontinue APMs (HR [95% CI]: 0.87 [0.77-0.98]) while hospitalization after 
LTCF admission increased the risk of APM discontinuation (HR [95% CI]: 1.12 [1.01-1.24]).  At 
the start of follow-up the risk of APM discontinuation was 4.80 (95% CI: 3.92-5.88) times 
greater among residents with hospitalization prior to LTCF admission.  This difference 
dissipated after two years (HR [95% CI]: 0.88 [0.76-1.01]). 
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 Facility type and location were significantly associated with APM discontinuation.  
Facilities that were affiliates (i.e., private, non-profit) had a higher APM discontinuation rate 
(HR [95% CI]: 1.12 [1.01-1.24]) than facilities that were amalgamates (i.e., publicly run).  The 
risk of APM discontinuation within the Regina Qu’Appelle Health Region (HR [95% CI]: 1.26 
[1.01-1.57]) and Saskatoon Health Region (HR [95% CI]: 1.59 [1.30-1.95]) was greater than all 
other health regions at the start of follow-up.  Over time this effect diminished and the APM 
discontinuation rates among the Regina Qu’Appelle (HR [95% CI]: 0.93 [0.78-1.11] and 
Saskatoon (HR [95% CI]: 0.87 [0.74-1.04]) Health Regions were no different than other health 
regions. 
4.4 Alternate definitions of APM discontinuation 
 
The alternate definitions of APM discontinuation were used in the Cox models; the 
estimated HRs did not change meaningfully for most of the explanatory variables. (Appendix F).  
When APM discontinuation was defined with a shorter non-exposure period all of the age 
categories had an increased risk of discontinuation (Table E1).  The HRs for age categories when 
defined using the longer definition of discontinuation were similar to the primary definition.  The 
overall trend of later index years being associated with a lower risk of discontinuation was 
consistent regardless of the definition of discontinuation that was adopted.  No change in the 
association between sex and APM discontinuation was observed.  Comorbidity variables did not 
differ between the primary APM discontinuation definition and the alternate definitions.  The 
shorter definition resulted in the HRs for residents with moderate or severe cognitive impairment 
having larger HRs during the first year of follow-up.  After two years the HRs were similar for 
the primary and alternate definitions of APM discontinuation.  No change in HRs was noted for 
the resident’s M S-CBP score.  Additionally, drug exposure, health care utilization, and LTCF 
variables exhibited no large differences in HRs comparing analyses using the primary and 
alternate definitions of APM discontinuation. 
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CHAPTER 5 – DISCUSSION 
 
5.1 Summary  
 
 The objectives of this research were to describe how APMs were utilized and 
discontinued by residents of LTCFs, what factors were predictive of APM discontinuation, and 
examine the sensitivity of the results to the definition of APM discontinuation.  Among the 
LTCF residents dispensed an APM, relatively few discontinued this medication during the EOR.  
The facility-specific percentages of LTCF residents discontinuing APMs did not differ 
substantially between facilities.  Additionally, facility-specific discontinuations did not vary 
substantially by facility characteristics like affiliation, location, or size.  Discontinuation was 
highest early after the index dispensation, but many discontinuations did not occur until several 
years had passed.  The variables that contributed the most to understanding the APM 
discontinuation were demographic, comorbidity, behavioural, and drug exposure variables.  The 
measured associations of APM discontinuation accounted for non-proportional hazards, which 
were observed to converge over time.  Therefore, the associations of the explanatory variables 
with APM discontinuation are the most relevant in the period of time shortly after APM 
initiation. 
 
5.2 Interpretation 
 
Among all residents that were eligible to be dispensed an APM and included in this 
study, more than one third were dispensed an APM during their EOR in a LTCF.  This is a larger 
percentage of APM users than other estimates of APM utilization derived from Canadian LTCF 
residents.
11-15
  It is also larger than the estimated 28.8% of LTCF residents dispensed an APM 
reported by Schneider-Linder et. al., which was a study of APM initiation among SK residents of 
LTCFs.
93
  These differences arose because cohort members in the current study were allowed to 
transfer between facilities within 60 days of their first admission date.  If this study right 
censored individuals on their transfer date the estimated percentage of APM users would 
decrease.  Dispensation of APMs occurred within 22 days for 50% of the cohort, and within 90 
days for 76.6% of the cohort, indicating that most residents are dispensed APMs shortly after 
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admission to a LTCF.  The results also suggest that cohort members received regular APM 
dispensations; the vast majority of the cohort received more than one dispensation (88.2%) and 
the largest gap between dispensations was ≤ 70 days for three-quarters of residents.  
Dispensation patterns revealed that for 58.9% and 28.9% of residents the first APM dispensed 
was the atypical agent risperidone or quetiapine, respectively.  This result is very similar to the 
result found by Schneider-Linder et. al., in which it was estimated that 62.4% of LTCF residents 
were dispensed risperidone and 23.0% were dispensed quetiapine.
93
   
Variation in APM discontinuation rates across facilities was modest and ranged from 5% 
to 30%.  Some facilities had low discontinuation rates close to 0%, while other had high 
discontinuation rates close to 100%.  In both cases these rates were a consequence of a small 
number of residents within the facilities. There was relatively little variation in the facility 
specific discontinuation percentages by affiliation, location, and size.  Additionally, while the 
test of the presence of a clustering effect of patients within LTCFs was statistically significant 
the magnitude of the clustering effect was small.  The estimated covariance range from 0.064 to 
0.111, indicating that both the heterogeneity between LTCFs and the association between 
residents in the same LTCF were small.  It is possible that clustering is underestimated because 
of the facilities with high or low discontinuation rates, but given the small number of individuals 
with such facilities it would not be expected to substantially alter the finding that the size of the 
clustering effect of residents in facilities is small. 
Analyses stratified by dementia diagnosis were investigated because residents with 
dementia are more likely to receive antipsychotics,
13,59-61
 and make up a large proportion of the 
LTCF population.
5
  However, estimates of discontinuation among residents with and without 
dementia were identical.  Analyses stratified by schizophrenia diagnosis were of interest because 
previous research has indicated that psychosis can be associated with APM utilization.
59
  The 
descriptive analysis showed that discontinuation was slightly higher among those without 
schizophrenia, but was not appreciably different from those with schizophrenia.  In SK people 
are assigned to a LTCF based on where the first available bed occurs, which may not always 
coincide with the preference of the patient.  However, residents may transfer to their preferred 
LTCF after their initial admission.  Stratification by transfer status did not reveal differences in 
the percentage of residents discontinuing APMs.  Stratification by prior antipsychotic exposure 
was important to consider because prevalent users are expected to be more adherent to their 
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therapy than novel users.
94
  This means that the analysis conducted with the residents without 
prior APM exposure represent a new user cohort and the results will be free from survivor bias.
94
  
No substantial differences in overall APM discontinuation were noted between residents without 
APM exposure prior to LTCF admission and residents that did receive an APM dispensation.  
Stratification by time to APM dispensation showed a possible trend towards the percentage of 
discontinuations increasing with longer times to initiation.  Since residents with a greater medical 
need for an APM could be expected to receive an APM sooner it is possible that that they are 
also less likely to discontinue APMs.  However, residents initiating more than 90 days after 
admission were unlikely to have prior dispensations, while those initiating APMs with 0-30 or 
31-90 days were more likely to have prior APM dispensations.   Since novel users of APMs are 
expected to discontinue APMs more than prevalent users of APMs,
94
 it is possible that the 
differences in discontinuation by time to initiation strata are driven by this effect. 
Discontinuation of APMs was also characterized by the EOR, which was found to extend 
over multiple years for many cohort members.  Calculating the percentage of APM 
discontinuation by EOR quintile highlighted a trend where APM discontinuation increased with 
EOR quintile length.  This trend was observed when the analysis was stratified by patient 
characteristics such dementia diagnosis, schizophrenia diagnosis, transfer to a new LTCF, 
exposure to APMs before LTCF admission, and days to APM initiation.    The results of this 
analysis are partially biased, primarily in the first EOR quintile, due to the presence of immortal 
time.  This occurred because the EOR includes the time to APM initiation, during which it is not 
possible for discontinuation to occur.  However, the EOR quintiles are not likely to be strongly 
influenced by immortal time bias because the majority of the cohort (76.6%) initiated APMs 
within 90 days of LTCF admission.    Additionally, it should be noted that long EORs are not 
unique to this study, and have been reported among residents of nursing homes in England.
95
   
The analysis of APM discontinuation across time to event quintiles revealed that 
discontinuation was greatest shortly after the first APM dispensation.  Additionally, the 
percentage of discontinuers decreased with increasing lengths of the time.  Most of the APM 
discontinuations (77.0%) in the first time to event quintile (1-55 days) can be attributed to cohort 
members with only a single dispensation for an APM.  Cohort members without dementia had a 
greater rate of discontinuation within the first time quintile than individuals with dementia.  
Since a greater proportion of patients with dementia have been documented to utilize APMs,
59-61
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it is not surprising that APMs are discontinued quickly among those without dementia.  
Residents without a diagnosis of schizophrenia had a greater percentage of discontinuations in 
the first time quintile than residents with a schizophrenia diagnosis.  This would be expected 
from the recommended clinical management of patients with schizophrenia.  However, 
discontinuation of APMs among schizophrenia patients has been found to be high, although most 
previous studies focused on a younger population.
43-45
  Cohort members with no prior APM 
exposure or who initiated APMs more than 90 days after admission had the highest rates of 
discontinuation within the first time to event quintile.  As noted previously, these two 
characteristics are related and the increase in discontinuation may be due to these individuals 
being novel users of APMs, whom are possibly at higher risk of discontinuation.
94
  These results 
should also be interpreted in combination with the results from the EOR quintile and time to 
APM initiation analyses.  Together they suggest that most residents initiate APMs quickly, some 
will discontinue APMs soon after initiation, but many do not and continue to receive these agents 
over a long period of time. 
Controlling for censoring using the KM product limit estimator of survival probability 
estimated median time to discontinuation was 6.5 years.  This indicates that after the index APM 
many residents continue to receiving dispensations for a long period of time, which is consistent 
with the simpler descriptive analyses of discontinuation counts by time to event and EOR 
quintiles.  Increasing the specificity of the APM discontinuation definition by lengthening the 
non-exposure period produced an expected decrease in the number of discontinuers, and an 
increase in the median time to discontinuation.  Conversely, APM discontinuations were 
increased and the median time to discontinuation shortened when a shorter non-exposure period 
defined discontinuation, because the sensitivity of the definition increased.  It is necessary to 
note that the interpretation of the results from the shortened time to APM discontinuation warrant 
caution.  This is because if discontinuation were being determined prospectively it would not be 
known which APM dispensation was going to be the last dispensation.  Therefore, this definition 
provides a lower bound for APM discontinuation in this study.  Overall, the primary and 
alternate definitions of discontinuation all produced results showing low discontinuation and a 
long discontinuation time. 
The modeling results indicated that differences in APM discontinuation were partially 
explained by the resident demographics, comorbid conditions, behavioural traits, and prior drug 
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exposures.  The AIC decreased by > 10 for both partially and sequentially adjusted models when 
demographic, comorbid, behavioural, and drug exposure variables were added to the model, 
providing some indication of improvement in model fit.
96
  This was supported by statistically 
significant LRTs.  However, the SBC increased, providing conflicting evidence about which 
model provided the best fit to the data.  There was limited evidence that the variables 
characterizing health care utilization and LTCF features was associated with alternate definitions 
of APM discontinuation.  The AIC decreased slightly when health care utilization variables were 
added to the partially and sequentially adjusted models, which provides only moderate evidence 
that these variables contribute meaningfully to model fit.  The LRTs for health care utilization 
variables were significant, but once again the SBC increased.  Models including LTCF 
characteristics exhibited an AIC that decreased minimally, or even increased, non-significant 
LRTs, and an increasing SBC.  Therefore, there is limited evidence to suggest that APM 
discontinuation is associated with the LTCF characteristics included in this study.  Since the 
SBC strongly favours more parsimonious models and depends on sample size
97
 the information 
gained from this set of variables was minimal.  Model discriminative performance was assessed 
with the c-statistic.
89
  The model with only demographic variables had the largest c-statistic, 
indicating excellent discriminative performance
91
, but more complex models resulted in a slight 
decrease in model discrimination.  Others have reported that in order for the c-statistic to 
increase, an important predictor must enter the model,
98
 and that after a baseline model with 
good discrimination has been built only small increases can be expected with the addition of 
variables.
99
  Therefore, the very good discriminative performance seen with the baseline 
demographic model in this study suggests that the c-statistic might not be expected to increase 
substantially.  The observed decrease in the c-statistic with increasing model complexity may be 
due to the fact that the statistic is calculated based on all usable pairs of rank ordered observed 
and predicted survival.
89
  This means that pairs of observations compare all event vs. event and 
event vs. non-event individuals, and are concordant when observed and predicted survival times 
are in the same order.  The results clearly indicate that the addition of more variables to the 
regression model changes the predicted survival and results in more discordant pairs, thereby 
lowering the c-statistic.  This may be due to the long time to event observed for some of the 
members of the cohort.  These results are not expected to be influenced by a violation of 
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independence, because initial analyses showed very little clustering indicating a minimal 
association between residents within the same LTCF. 
The regression analyses identified a number of variables associated with APM 
discontinuation.  Overall, age was not strongly associated with APM discontinuation.  This 
concurs with research indicating no age effect with APM utilization,
10,13
 but disagrees with 
research finding decreased use of APMs with age.
57-59
  Index fiscal years closer to the study end 
date were associated with a lower risk of APM discontinuation.  This is likely due to the long 
time to event within the cohort, which would decrease the likelihood that an individual with late 
admission into the study would discontinue.  In this study women were found to have a greater 
risk of discontinuation at the start of follow-up.  Previous research has been mixed, but others 
have identified that women utilize APMs less than men, which would agree with an increase in 
discontinuation
13,59
  This relationship could arise if men had more severe dementia upon LTCF 
admission than women, which could require the treatment of BPSD with APMs.  However, some 
research has not identified differences between men and women in APM utilization,
57
 which was 
observed after 2 years of follow-up in this study. 
Dementia was associated with a lower risk of APM discontinuation, which concurs with 
APM utilization research that has found greater APM use among those with dementia.
13,60,61
  
Previous research has found that increased comorbidity, measured with the Charlson index, is 
associated with less APM utilization.
13
 Overall, the Charlson index indicated relatively low 
comorbidity in the cohort and no association with APM discontinuation was found.  This could 
arise because the Charlson index was designed to predict mortality after hospitalization, and has 
not been validated as a predictor of drug adherence.  No other comorbidity variables were 
associated with discontinuation in this study.   
Cognitive impairment and challenging behaviours also characterized the study cohort.  
Those with greater cognitive impairment were more likely to discontinue APMs at the start of 
follow-up, which is consistent with the finding that APMs are utilized less among those with 
cognitive impairment.
59
  Severe behavioural problems have previously been reported to be 
associated with more APM utilization.
59
  However, an inconsistent relationship between APM 
discontinuation and the MDS-CBP was identified from these results.  The study identifying the 
relationship between behaviour and APM use relied on a different measurement scale, which 
could contribute to the discrepancy observed. 
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 Exposure to APMs before LTCF admission was associated with increased risk of 
discontinuation at the start of follow-up, particularly among individuals who were dispensed an 
APM within 30 days of admission.  Over time this risk decreased, and resulted in prior APM 
exposure being associated with less of a risk of discontinuation.  Since Schneider-Linder et. al. 
found that prior APM exposure was associated with APM dispensations
93
 it could be expected 
that previous APM dispensations would have the opposite relationship with discontinuation.  A 
possible explanation is that after admission when resident’s medications are reviewed it could be 
determined that the APM is not necessary, leading to discontinuation.  But if APMs were 
continued after a medication review then discontinuation would be less likely to occur.  The 
other drug exposure that was associated with increased APM discontinuation was cholinergic 
agents.  Since these agents are used in the treatment of dementia, this result could reflect a 
discontinuation of APMs used to treat BPSD due to the cholinergic agent improving the 
symptoms of dementia. 
Resident transfers were associated with decreased APM discontinuation.  This transfer 
variable was included to account for residents moving to a new LTCF because they have a 
preferred facility.  It is not clear how transferring LTCFs would lead to a decrease in APM 
discontinuation.  A possible explanation is that patient characteristics linked to discontinuation 
such as comorbidity/health care needs also influence the likelihood transferring.  Alternatively, 
residents that transfer may be more likely to reside in a facility with increased capacity to 
manage patients without the use of APMs.  Hospitalization before LTCF admission was 
associated with an increased risk of APM discontinuation at the start of follow-up.  These 
patients could have a higher degree of comorbidity, which has been linked to lower APM 
utilization.
13
  It would therefore be consistent that they also discontinue APMs more than cohort 
members without hospitalization before LTCF admission.  Similarly, hospitalization after LTCF 
admission is associated with increased risk of APM discontinuation.  Hospitalized residents 
could have more comorbidities or their medication regimen could be changed after discharge to 
discontinue APMs.   However, a possible explanation for this relationship is the presence of 
immeasurable time bias arising from the inability to observe pharmacologic dispensations during 
hospital stays.
100
  This would be expected to increase discontinuation, as measured in this study, 
in some situations.  For example, if a resident was hospitalized and died they could be classified 
as a discontinuer, even if they continued to receive APMs in hospital.  However, it is important 
 51 
 
 
to be cautious in the interpretation of these health care utilization variables because they 
contributed little information to the overall model fit. 
Amongst the LTCF characteristics, only the facility location showed an association with 
APM discontinuation.  This could be related to differential aspects of care provided within 
LTCFs of these health regions.  For example, if facilities within or near the urban centres of 
Regina and Saskatoon had the infrastructure, staff and procedural policies to facilitate the 
management of residents without APMs, they would be expected to reduce the use of these 
agents. 
The sensitivity analyses included provide further insight into the results.  The sensitivity 
analysis of APM discontinuation revealed few changes between the model using the primary 
definition of discontinuation and the models that used alternate definitions.  Residents dispensed 
4-6 or ≥ 7 medications were found to have a lower risk of discontinuation when discontinuation 
was defined using a 70 day non-exposure gap.  Interestingly, previous research has found that 
increased polypharmacy decreased adherence to drugs which is opposite of this result.  
Transferring LTCFs became non-significant for both alternate definitions of discontinuation.  
Additionally, discontinuation was no longer greater among residents in the Regina Qu’Appelle 
health region at the start of follow-up.  The change in the results for LTCF transfer and facility 
location also suggest caution in the interpretation of the main results for these variables. 
The sensitivity analysis examining positive and negative correlations between 
discontinuation and censoring indicated that few variables were sensitive to severe violation of 
this assumption (Appendix G).  Most of the changes in the HRs indicated that the results became 
non-significant for both positive and negative correlation.  Specifically this impacted index fiscal 
year, last cholinergic dispensation, and LTCF transfer.  Age and MDS-CBP became significant 
under the model for positive correlation.  The primary results suggested the possibility that 
increasing challenging behaviour could be related to decreased discontinuation.  The increased 
risk of discontinuation for all levels of the MDS-CBP variable reverses this trend and suggests 
that this variable is sensitive to the independent censoring assumption.  Additionally, the MDS-
CPS variable was very sensitive to both positive and negative correlation models over all points 
in time.  Finally, the risk of discontinuation was found to increase for both positive and negative 
models of prior APM exposure.  The results suggest that there is mild sensitivity to positive and 
negative correlation when the last dispensation was more than 30 days before admission.  
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Overall, the variables that are most sensitive to violation of the non-informative censoring 
assumption are the index fiscal year and behavioural characteristics. 
Due to violation of the proportional hazards assumption a post-hoc analysis truncating 
follow-up time to 6 months was conducted to limit the violation of this assumption (Appendix 
H).  The results were very similar to those obtained from the fully adjusted model without 
covariate-time interactions.  Index fiscal year, LTCF transfer, and hospitalization after LTCF 
admission were no longer significantly associated with APM discontinuation.  Residents with 
schizophrenia or mood disorders were less likely to discontinue APMs, as were residents with 
increasing scores on the MDS-CBP.  However, the estimated effect of sex, cognitive impairment, 
and prior APM exposure did not have any agreement with the results from the model where these 
variables interacted with time.  Overall, the results from the model evaluating only 6 months of 
follow-up time were more similar to the results from the analysis not including covariate time-
interactions.  This could indicate that even over this shorter time frame the results may still be 
influenced by non-proportional hazards. 
 
5.3 Study strengths and limitations 
 
 One strength of this study is the use of population-based data that captures information on 
all residents of SK, thereby minimizing selection bias and improving the generalizability of the 
results.  Additionally, administrative data in SK have been shown to be accurate and complete 
for population-based research in several studies.
72-78
   However, our study population only 
included senior citizens, so the results should not be considered representative of a younger 
LTCF population.  Additionally, the inferential analysis included complete cases only, which 
would be expected to introduce selection bias and reduce generalizability.   
 A wide range of explanatory variables were included in this study, which enabled 
analytic control of confounding.  However, some variables could not be measured, which would 
result in a residual confounding effect in the analysis.  Variables describing health behaviours 
and individual-level socioeconomic status were not measureable for LTCF residents within the 
databases used for this research.  Diagnosis codes for the definition of psychiatric disease 
comorbidities were limited to 3 or 4 digits, and the ability to detect active disease cases has been 
shown to be limited in administrative data for residents of long-term care.
101
  Specifically, the 
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sensitivity of diagnostic codes for dementia, anxiety disorders, and depression is low, but 
specificity is high.
101
  Schizophrenia was the only psychiatric comorbidity with both high 
sensitivity and specificity.
101
  Therefore, misclassification bias was expected within the diagnosis 
variables, and using these variables would not result in complete removal of confounding effects.  
There could also be residual confounding due to unmeasured facility level factors.  Examples 
include staffing levels or the presence of special care units for patients with dementia in a LTCF.  
Information about the indication for prescribing, if the prescription was intended to be used as 
needed (i.e., PRN), and in-hospital drug dispensations are also not available.  Therefore, 
dispensation is only a proxy measure of drug exposure.  Furthermore, not all medications are 
covered by the SK drug plan and private purchase of other agents is not captured in the study 
data sources.  This has the potential for incorrectly classifying a resident continuing to receive 
APMs as discontinuing, which is a source of information bias due to incomplete measurement.    
Overall, these errors in measurement can lead to misclassification in the exposures and 
outcomes, which could bias the estimated effect sizes towards the null.
102
   
 Discontinuation of APMs was operationally defined to occur after the last known APM 
dispensation. This measure could not be validated, and therefore may result in some 
misclassification bias.  An additional source of misclassification is that some individuals were 
noted to have large gaps (> 1 year) between APM dispensations, and these individuals could 
reasonably be considered to have discontinued APMs.  Alternate definitions of APM 
discontinuation only varied the number of non-exposure days to 0 and 70, and additional 
evaluations of APM discontinuation would strengthen the results by adding a further 
understanding of the impact of outcome misclassification.  Shortening the non-exposure period 
to 0 days will increase the sensitivity of the outcome definition.  Consequently, more 
discontinuations were observed with this definition and the median time to discontinuation was 
shorter.  Lengthening the non-exposure period to 70 days will increase the specificity of the 
outcome definition.  The analytic results were largely robust to these alternative definitions of 
APM discontinuation.  Given that the number of cohort members that may be misclassified due 
to large gaps between APM dispensations is small (n = 148), one might hypothesize that the 
results would not change if these individuals were classified as discontinuers. 
 One of the issues encountered in this project was non-proportional hazards.  Hazards 
were found to converge over time, which is a phenomenon has been noted in other epidemiologic 
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research with long follow-up times.
103
  The reported HRs would be expected to be biased in this 
situation, most likely towards the null.  This is because the reported HR is an average of the HR 
at all event times.
104,105
  This limitation was addressed by modeling the non-proportional hazards 
with covariate-time interactions, and conducting an analysis with follow-up time truncated at 6 
months. 
The assumption of independent censoring was addressed in this project by conducting a 
sensitivity analysis.  While some variables were found to be sensitive to this assumption the 
degree of violation of this study is not likely as extensive as those used in the sensitivity analysis. 
It is likely safe to assume that censoring due to the study ending is independent of APM 
discontinuation.  Additionally, given the small number (n = 11) of individuals lost to follow-up 
due to health coverage it is unlikely to have a meaningful impact on the model results and 
interpretation.  Discharge from long-term care represents the end of the risk period for the 
resident, which precludes APM discontinuation from being observed.  These individuals could 
represent a healthier population of LTCF residents since they were no longer receiving long-term 
care.  The probability of APM discontinuation among these residents may not be accurately 
represented by the cohort members remaining in a LTCF.  If APM discontinuation is more likely 
among individuals that are discharged from long-term care then the probability of APM 
discontinuation is underestimated.  This would correspond to a positive correlation between 
event time and censoring due to LTCF discharge.  Death also prevents the observation of APM 
discontinuation, and can be considered a competing risk, which would bias the results of the 
analysis.
106,107
   
 
5.4 Significance and future research 
 
This study revealed APMs are utilized regularly over a long period of time among the 
LTCF incident resident population.  This phenomenon may be affecting one-third of residents in 
LTCFs within the province of SK, Canada.  In the examination of APM discontinuation we have 
identified that about one-fifth of the LTCF residents that are dispensed an APM will stop 
receiving these pharmaceuticals.  It is possible that discontinuation may be higher, because this 
work adopted a relatively conservative definition of discontinuation.  However, more liberal 
definitions were found to be unlikely to change this finding substantially.  The results were 
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complex to interpret because the proportional hazards assumption was violated.  Variables 
describing resident demographics, comorbidity, drug exposure, and behavioural characteristics of 
the residents explained APM discontinuation the best.  Finally, the analytic results were robust to 
different definitions of APM discontinuation. 
This study contributes to the knowledge about APM utilization among senior citizens in 
LTCFs by describing the long-term use of these drugs once they are started.  This is a novel 
finding that has not been previously reported.  Since discontinuation was low the results imply 
that APM withdrawal was not occurring for most residents, and presents an opportunity for 
clinicians to consider changes to the pharmacotherapy of LTCF residents that could be beneficial 
for their health.  However, the evidence for the clinical benefits of APM discontinuation are 
mixed, and this study only suggests that there could be opportunities to do so in the long-term 
care population.  Additionally, APMs may be utilized to address aggressive behaviours that 
endanger others, in which case discontinuation would not be recommended. 
Future research opportunities are numerous.  First, a deeper understanding of how patient 
characteristics contribute to the discontinuation of APMs could be obtained by including time-
varying covariates, particularly for such patient characteristics as dementia diagnosis, cognitive 
status, problem behaviours, psychotropic drug dispensations, hospitalization, and facility 
characteristics.  Additionally, the finding of increased discontinuation among residents with prior 
cholinergic exposure could be investigated further because this could indicate that APMs are 
being discontinued when dementia is treated.  Also, the limitations faced due to non-proportional 
hazards could be addressed using weighted Cox regression techniques, with the benefit that the 
HRs would be more easily interpretable.
104,105
  Additionally, this approach could allow for a 
more detailed and accurate assessment of interactions between predictor variables.  A competing 
risks analysis could help remove some of the bias that is introduced by assuming that censoring 
is completely non-informative.
106,107
  Additional information about the administration of APMs 
could contribute a further understanding of the true utilization of these agents in long-term care.  
This could potentially be assessed using the RAI-MDS which documents antipsychotic 
administration during a week-long observation period, or with the medication administration 
record.  It is also possible that the dose of APMs administered to LTCF residents may change 
over time.  This is an important issue because clinical recommendations for individuals with 
dementia receiving APMs suggest tapering the dose if the patient is behaviourally stable.  
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Additionally, further investigation of APM discontinuation among residents with dementia or 
schizophrenia is warranted because both diseases were common and would be expected to 
influence APM utilization.  This study also noted that some LTCF residents only received a 
single APM dispensation, and the factors contributing this pattern of APM utilization could be 
important for understanding discontinuation.  Some facilities were found to have high and low 
discontinuation rates.  Further investigation of these specific facilities could elucidate if the 
observed rates are truly an artifact of small numbers of residents (i.e., unstable rates), or if these 
LTCFs are true outliers.  Observational studies have also not been performed to replicate the 
experimental findings of reduced mortality due APM discontinuation, which would further 
examine the hypothesis that APMs are detrimental for some LTCF residents.  Finally, this study 
focused on residents of LTCFs that are senior citizens; future work focusing on a younger LTCF 
population would be of interest. 
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APPENDIX A – PSYCHOTROPIC DRUGS COVERED BY THE SK DRUG FORMULARY 
DURING THE STUDY PERIOD 
 
Table A1. Antipsychotics, antidepressants, benzodiazepines, anticholinergics, and cholinergic medications 
covered by the SK provincial drug formulary during the study period. 
 SK Drug Formulary Edition
a
 
AHFS Code Generic drug name 52 53 54 55 56 57 58 59 60 61 62 
Antipsychotics
b
            
28:16.08 Aripiprazole           • • 
28:16.08 Chlorpromazine • • • • • • • • • • • 
28:16.08 Clozapine • • • • • • • • • • • 
28:16.08 Flupenthixol decanoate • • • • • • • • • • • 
28:16.08 Flupenthixol dihydrochloride • • • • • • • • • • • 
28:16.08 Fluphenazine decanoate • • • • • • • • • • • 
28:16.08 Fluphenazine enanthate •           
28:16.08 Fluphenazine HCL • • • • • • • • • • • 
28:16.08 Haloperidol • • • • • • • • • • • 
28:16.08 Haloperidol decanoate • • • • • • • • • • • 
28:16.08 Loxapine succinate • • • • • • • • • • • 
28:16.08 Olanzapine • • • • • • • • • • • 
28:16.08 Paliperidone palmitate          • • 
28:16.08 Pericyazine • • • • • • • • • • • 
28:16.08 Perphenazine • • • • • • • • • • • 
28:16.08 Pimozide • • • • • • • • • • • 
28:16.08 Pipotiazine palmitate • • •  • • • • • • • 
28:16.08 Prochlorperazine • • • • • • • • • • • 
28:16.08 Quetiapine • • • • • • • • • • • 
28:16.08 Risperidone • • • • • • • • • • • 
28:16.08 Thioridazine • • • •        
28:16.08 Thiothixene • • • • • • • • • • • 
28:16.08 Trifluoperazine • • • • • • • • • • • 
28:16.08 Ziprasidone        • • • • 
28:16.08 Zuclopenthixol acetate • • • • • • • • • • • 
28:16.08 Zuclopenthixol decanoate • • • • • • • • • • • 
28:16.08 Zuclopenthixol dihydrochloride • • • • • • • • • • • 
28:24.92 Methotrimeprazine • • • • • • • • • • • 
Antidepressants
c 
           
28:16.04 Amitriptyline • • • • • • • • • • • 
28:16.04 Bupropion HCL • • • • • • • • • • • 
28:16.04 Citalopram hydrobromide • • • • • • • • • • • 
28:16.04 Clomipramine HCL • • • • • • • • • • • 
28:16.04 Desipramine HCL • • • • • • • • • • • 
28:16.04 Doxepin HCL • • • • • • • • • • • 
28:16.04 Duloxetine hydrochloride        • • • • 
28:16.04 Fluoxetine • • • • • • • • • • • 
28:16.04 Fluvoxamine maleate • • • • • • • • • • • 
28:16.04 Imipramine • • • • • • • • • • • 
28:16.04 Maprotiline • • • • • • • • • • • 
28:16.04 Mirtazapine • • • • • • • • • • • 
28:16.04 Moclobemide • • • • • • • • • • • 
28:16.04 Nefazodone • •          
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Table A1. Antipsychotics, antidepressants, benzodiazepines, anticholinergics, and cholinergic medications 
covered by the SK provincial drug formulary during the study period. 
 SK Drug Formulary Edition
a
 
AHFS Code Generic drug name 52 53 54 55 56 57 58 59 60 61 62 
Antidepressants
c 
           
28:16.04 Nortriptyline • • • • • • • • • • • 
28:16.04 Paroxetine HCL • • • • • • • • • • • 
28:16.04 Phenelzine SO4 • • • • • • • • • • • 
28:16.04 Sertraline hydrochloride • • • • • • • • • • • 
28:16.04 Tranylcypromine SO4 • • • • • • • • • • • 
28:16.04 Trazodone • • • • • • • • • • • 
28:16.04 Trimipramine • • • • • • • • • • • 
28:16.04 Venlafaxine HCL • • • • • • • • • • • 
Benzodiazepines
d 
           
28:12.08 Clonazepam • • • • • • • • • • • 
28:12.08 Nitrazepam • • • • • • • • • • • 
28:12.92 Clobazam • • • • • • • • • • • 
28:24.08 Alprazolam • • • • • • • • • • • 
28:24.08 Bromazepam • • • • • • • • • • • 
28:24.08 Chlordiazepoxide • • • • • • • • • • • 
28:24.08 Clorazepate dipotassium • • • • • • • • • • • 
28:24.08 Diazepam • • • • • • • • • • • 
28:24.08 Flurazepam HCL • • • • • • • • • • • 
28:24.08 Lorazepam • • • • • • • • • • • 
28:24.08 Oxazepam • • • • • • • • • • • 
28:24.08 Temazepam • • • • • • • • • • • 
28:24.08 Triazolam • • • • • • • • • • • 
Anticholinergic agents            
12:08.04 Benztropine mesylate • • • • • • • • • • • 
12:08.04 Ethopropazine • • • • • • • • • • • 
12:08.04 Procyclidine HCL • • • • • • • • • • • 
12:08.04 Trihexyphenidyl HCL • • • • • • • • • • • 
12:08.08 Dicyclomine HCL • • • • • • • • • • • 
12:08.08 Hyoscine butylbromide • • • • • • • • • • • 
12:08.08 Ipratropium bromide • • • • • • • • • • • 
12:08.08 Ipratropium bromide/salbutamol SO4 • • • • • • • • • • • 
12:08.08 Propantheline bromide • • •         
12:08.08 Tiotropium bromide monohydrate   • • • • • • • • • 
Cholinergic agents            
12:04.00 Bethanechol chloride • • • • • • • • • • • 
12:04.00 Donepezil HCL
e • • • • • • • • • • • 
12:04.00 Galantamine hydrobromide
e • • • • • • • • • • • 
12:04.00 Neostigmine bromide • • • • • • • • • • • 
12:04.00 Pyridostigmine bromide • • • • • • • • • • • 
12:04.00 Rivastigmine
e • • • • • • • • • • • 
Abbreviations – AHFS: American hospital formulary system, APM: antipsychotic medication, SK: Saskatchewan.  
Notes – a: Drug formulary edition 52 covers begins October 2002 and drug formulary edition ends March 2013.  
b: The first step of identifying APMs was to use the AHFS code 28:16.08, which included the APM asenapine.  
However, asenapine was not covered during the study period and is not included in this study.  Additionally, other 
APMs that are not covered by the provincial formulary include promazine and lurasidone.  c: Antidepressants that 
are not covered by the provincial formulary include desvenlafaxine and escitalopram.  d: The benzodiazepine 
midazolam is only covered as part of hospital benefit drug list in formulary editions 52-60, but it is not captured 
with the prescription drug database.  e: The AHFS code this drug is 92:00.00 in the formulary editions 52 to 57.    
Symbols – •, indicates that the prescription drug is covered within the indicated edition of the SK drug formulary. 
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APPENDIX B – ICD CODES DEFINING PSYCHIATRIC COMORBIDITIES 
 
Table B1. ICD-9 and -10-CA codes for psychiatric comorbidities 
Diagnosis ICD-10-CA ICD-9 
 
Dementia 
F00.0, F00.1, F00.2, F00.9 ; F01.0, F01.1, F01.2, F01.3, 
F01.8, F01.9; F02.0, F02.1, F02.2, F02.3, F02.4, F02.8; 
F03; F05.1; G30.0, G30.1, G30.8, G30.9; G31.0, G31.1, 
G31.8, G31.9; G32.8; R54 
290, 331, 797 
 
Schizophrenia 
F20.0, F20.1, F20.2, F20.3, F20.4, F20.5, F20.6, F20.8 
F20.9; F21; F23.0, F23.1, F23.2, F23.3, F23.8, F23.9; 
F25.0, F25.1, F25.2, F25.8, F25.9; F28; F29; F32.3; F33.3 
295, 298 
 
Depression 
F30; F31.0, F31.1, F31.2, F31.3, F31.4, F31.5, F31.6, 
F31.7, F31.8, F31.9; F32.1, F32.2, F32.3, F32.8, F32.9; 
F33.0, F33.1, F33.2, F33.4, F33.8, F33.9; F34.8, F34.9; 
F38.0, F38.1, F38.8; F39 
296, 311 
 
 
 
Anxiety 
F04; F05.0, F05.8, F05.9; F06.0, F06.1, F06.2, F06.3, 
F06.4, F06.5, F06.6, F06.7, F06.8, F06.9; F22.0, F22.8, 
F22.9; F24; F32.0; F34.1; F40.0, F40.1, F40.2, F40.8, 
F40.9; F41.0, F41.1, F41.2, F41.3, F41.8, F41.9; F42.0, 
F42.1, F42.2, F42.8, F42.9; F44.0, F44.1, F44.2, F44.3, 
F44.4, F44.5, F44.6, F44.7, F44.8, F44.9; F45.0, F45.1, 
F45.2; F48.0, F48.1, F48.8, F48.9; F68.0; F84.0, F84.1, 
F84.3, F84.4, F84.5, F84.8, F84.9; F99 
293,294, 297, 299, 300 
 
 
 
 
Alcohol or 
drug abuse 
F10.0, F10.1, F10.2, F10.3, F10.4, F10.5, F10.6, F10.7, 
F10.8, F10.9; F11.0, F11.1, F11.2, F11.3, F11.4, F11.5, 
F11.6, F11.7, F11.8, F11.9; F12.0, F12.1, F12.2, F12.3, 
F12.4, F12.5, F12.6, F12.7, F12.8, F12.9; F13.0, F13.1, 
F13.2, F13.3, F13.4, F13.5, F13.6, F13.7, F13.8, F13.9; 
F14.0, F14.1, F14.2, F14.3, F14.4, F14.5, F14.6, F14.7, 
F14.8, F14.9; F15.0, F15.1, F15.2, F15.3, F15.4, F15.5, 
F15.6, F15.7, F15.8, F15.9; F16.0, F16.1, F16.2. F16.3, 
F16.4, F16.5, F16.6, F16.7, F16.8, F16.9; F17.0, F17.1, 
F17.2, F17.3, F17.4, F17.5, F17.6, F17.7, F17.8, F17.9; 
F18.0, F18.1, F18.2, F18.3, F18.4, F18.5, F18.6, F18.7, 
F18.8, F18.9; F19.0, F19.1, F19.2, F19.3, F19.4, F19.5, 
F19.6, F19.7, F19.8, F19.9; F55; G31.2; K70.0, K70.1, 
K70.2, K70.3, K70.4, K70.9 
291, 292, 303, 304, 305 
Extrapyramidal 
symptoms 
G10; F95.0, F95.1, F95.2, F95.8, F95.9 307, 333 
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APPENDIX C – ASSESSMENT OF THE PROPORTIONAL HAZARDS ASSUMPTION 
 
Table C1.  Pearson correlation coefficients of scaled Schoenfeld residuals and event time rank. 
 
Demographic 
 
Coefficient p-value 
Age   
 75-84 -0.03557 0.1610 
 85-94 -0.04017 0.1134 
 95 -0.03758 0.1387 
Sex   
 Female 0.07576 0.0028 
Index Fiscal Year   
    04/05 -0.06464 0.0108 
    05/06 -0.02920 0.2499 
    06/07 -0.05316 0.0361 
    07/08 -0.05989 0.0182 
    09/10 -0.01340 0.5977 
   10/11 -0.05766 0.0230 
   11/12 -0.03245 0.2010 
Comorbidity   
Dementia   
   Yes 0.05484 0.0307 
Schizophrenia   
   Yes 0.00821 0.7465 
Mood disorder   
   Yes 0.02519 0.3210 
Alcohol or drug abuse   
   Yes -0.03371 0.1842 
Extrapyramidal symptoms   
   Yes -0.02713 0.2851 
Charlson index   
   1-2 0.01597 0.5292 
   3-4 -0.00122 0.9618 
   5 0.00700 0.7829 
Level of care   
   Level 2 0.00309 0.9031 
   Level 3 0.01157 0.6486 
   Level 4 0.00394 0.8768 
AHFS drug category   
   4-6 0.00743 0.7697 
   7 -0.00810 0.7498 
Behavioural   
MDS-CPS   
   Moderately impaired (2-3) 0.08193 0.0012 
   Severely impaired (4-6) 0.10032 <.0001 
MDS-CBP   
   Mild (1-4) 0.00249 0.9217 
   Moderate (5-9) 0.04138 0.1030 
   Severe (10-14) 0.04242 0.0946 
   Extreme (15) 0.03793 0.1350 
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Table C1.  Continued   
 
Drug exposure 
 
Coefficient p-value 
Days to APM initiation after LTCF admission   
   31-90 days 0.01556 0.5400 
   > 90 days 0.01025 0.6864 
Last APM dispensation before LTCF admission   
    30 days 0.08662 0.0006 
   > 30 days 0.06965 0.0060 
Last antidepressant dispensation before LTCF admission   
    30 days -0.02876 0.2573 
   > 30 days -0.04015 0.1136 
Last benzodiazepine dispensation before LTCF admission   
    30 days 0.00026 0.9918 
   > 30 days -0.00782 0.7580 
Last anticholinergic dispensation before LTCF  admission   
    30 days -0.03890 0.1254 
   > 30 days -0.00914 0.7188 
Last cholinergic dispensation before LTCF admission   
    30 days 0.03120 0.2190 
   > 30 days -0.00621 0.8068 
Health care utilization    
Transfer to new LTCF   
   Yes -0.02823 0.2661 
Hospitalization prior to LTCF admission   
   Yes -0.06699 0.0082 
Hospitalization after LTCF admission   
   Yes -0.00742 0.7700 
LTCF   
Facility affiliation   
   Affiliate (private, non-profit) -0.03760 0.1384 
   Contract (private, for profit) -0.04316 0.0890 
Facility Health Region   
   Regina Qu’Appelle 0.07051 0.0054 
   Saskatoon -0.03176 0.2108 
Facility size   
   Small (1-35 beds) -0.03042 0.2308 
   Medium (36-100 beds) 0.01068 0.6741 
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APPENDIX D – ASSESSMENT OF POTENTIALLY INFLUENTIAL OBSERVATIONS 
FOR COX REGRESSION MODEL 
 
 
Figure D1.  Model deviance residuals from fully adjusted covariate time model plotted against follow-up time to 
evaluate the presence of potential outliers.   
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Table D1. Change in the estimated HR after removal of potentially influential data points.  
Variables
a 
Estimated 
Lower 
estimate
b 
Upper 
estimate
b 
Demographic HR HR  HR  
Age    
 75-84 1.19 1.17 1.22 
 85-94 1.34 1.32 1.37 
 ≥ 95 1.17 1.15 1.20 
 65-74 1.00 (Ref) N/A N/A 
Sex    
 Female 2.66 2.64 2.69 
 Male 1.00 (Ref) N/A N/A 
Index fiscal year    
 04/05 0.98 0.97 0.99 
 05/06 1.00 0.99 1.01 
 06/07 0.87 0.86 0.88 
 07/08 0.80 0.79 0.81 
 09/10 0.76 0.75 0.77 
 10/11 0.75 0.75 0.75 
 11/12 0.58 0.58 0.58 
 12/13
 
- - - 
 08/09 1.00 (Ref) N/A N/A 
Comorbidity    
Dementia     
 Yes 0.86 0.85 0.87 
 No 1.00 (Ref) N/A N/A 
Schizophrenia    
 Yes 1.01 1.01 1.01 
 No 1.00 (Ref) N/A N/A 
Mood disorder      
 Yes 0.94 0.94 0.94 
 No 1.00 (Ref) N/A N/A 
Alcohol or drug abuse    
 Yes 0.94 0.90 0.97 
 No 1.00 (Ref) N/A N/A 
Extrapyramidal symptoms     
 Yes 1.02 1.01 1.04 
 No 1.00 (Ref) N/A N/A 
Charlson index     
 1-2 0.94 0.93 0.95 
 3-4 0.99 0.98 1.00 
 ≥ 5 0.95 0.94 0.96 
 0 1.00 (Ref) N/A N/A 
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Table D1. Continued     
Comorbidity
 Estimated 
Lower 
estimate
b 
Upper 
estimate
b 
Level of care      
 Level 2 1.46 1.39 1.53 
 Level 3 1.32 1.25 1.39 
 Level 4 1.65 1.57 1.73 
 Level 1 1.00 (Ref) N/A N/A 
AHFS drug category     
 4-6 0.88 0.87 0.89 
 ≥ 7 0.90 0.89 0.91 
 0-3 1.00 (Ref) N/A N/A 
Behavioural    
MDS-CPS    
 Moderately impaired (2-3) 4.20 4.14 4.24 
 Severely impaired (4-6) 4.07 4.01 4.11 
 Minimally impaired (0-1) 1.00 (Ref) N/A N/A 
MDS-CBP    
 Mild (1-4) 1.16 1.15 1.18 
 Moderate (5-9) 0.95 0.94 0.96 
 Severe (10-14) 0.76 0.75 0.77 
 Extreme (≥ 15) 0.73 0.72 0.75 
 None (0) 1.00 (Ref) N/A N/A 
Drug exposure    
Days to APM initiation after LTCF admission    
 31-90 days 0.95 0.94 0.95 
 > 90 days 1.07 1.06 1.08 
 0-30 days 1.00 (Ref) N/A N/A 
Last APM dispensation before LTCF admission    
 ≤ 30 days 1.43 1.42 1.45 
 > 30 days 1.18 1.16 1.20 
 None in previous year 1.00 (Ref) N/A N/A 
Last antidepressant dispensation before LTCF admission   
 ≤ 30 days 1.12 1.11 1.13 
 > 30 days 1.05 1.04 1.06 
 None in previous year 1.00 (Ref) N/A N/A 
Last benzodiazepine dispensation before LTCF admission   
 ≤ 30 days 0.79 0.78 0.80 
 > 30 days 0.88 0.87 0.89 
 None in previous year 1.00 (Ref) N/A N/A 
Last anticholinergic dispensation before LTCF admission   
 ≤ 30 days 0.78 0.76 0.80 
 > 30 days 0.80 0.79 0.81 
 None in previous year 1.00 (Ref) N/A N/A 
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Table D1. Continued     
Drug exposure
 Estimated 
Lower 
estimate
b 
Upper 
estimate
b 
Last cholinergic dispensation before LTCF admission    
 ≤ 30 days 1.31 1.29 1.33 
 > 30 days 1.38 1.37 1.39 
 None in previous year 1.00 (Ref) N/A N/A 
Health care utilization    
Transfer to new LTCF    
 Yes 0.87 0.86 0.87 
 No 1.00 (Ref) N/A N/A 
Hospitalization prior to LTCF admission    
 Yes 4.80 4.75 4.85 
 No 1.00 (Ref) N/A N/A 
Hospitalization after LTCF admission    
 Yes 1.12 1.11 1.12 
 No 1.00 (Ref) N/A N/A 
LTCF    
Facility affiliation    
 Affiliate (private, non-profit) 1.16 1.15 1.17 
 Contract (private, for profit) 0.96 0.95 0.97 
 Amalgamate (public) 1.00 (Ref) N/A N/A 
Facility Health Region    
 Regina Qu'Appelle 1.26 1.25 1.28 
 Saskatoon 1.59 1.57 1.60 
 Other 1.00 (Ref) N/A N/A 
Facility size    
 Small (1-35 beds) 0.90 0.89 0.91 
 Medium (36-100 beds) 1.01 1.00 1.02 
 Large (> 100 beds) 1.00 (Ref) N/A N/A 
Abbreviations – AHFS: American hospital formulary system, APM: antipsychotic medication, HR 
(95% CI): Hazard ratio (95% confidence interval), LTCF: long-term care facility, MDS-CBP: 
minimum dataset challenging behaviour profile, MDS-CPS: minimum dataset cognitive performance 
scale.  Notes – a: Explanatory variables are grouped by concept, which is indicated by the bold-
italicized terms.  b: lower and upper estimated HR are based on the average of the 6 most extreme 
lower and upper scaled score residuals. 
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APPENDIX E – KAPLAN-MEIER SURVIVAL CURVES DEMONSTRATING NON-
PROPORTIONALITY OF HAZARDS 
 
 
Figure E1.  Kaplan-Meier survival probability by resident cognitive impairment. 
 
 
Figure E2.  Kaplan-Meier survival probability by last APM dispensation before LTCF admission. 
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Figure E3.  Kaplan-Meier survival probability by hospitalization prior to LTCF admission. 
 
 
Figure E4.  Kaplan-Meier survival probability by LTCF location. 
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APPENDIX F –COX PROPORTIONAL HAZARDS REGRESSION MODELS FOR 
ALTERNATE DEFINITIONS OF APM DISCONTINUATION 
 
Table F1.  Hazards ratios (HRs) and 95% confidence intervals (95% CIs) for fully adjusted Cox proportional 
hazards regression models with covariate time interactions for the assessment of model sensitivity to the 
definition of APM discontinuation. 
Explanatory variables
a Primary 
non-exposure gap
b 
Shorter  
non-exposure gap
b 
Longer  
non-exposure gap
b 
Demographic HR (95% CI) HR (95% CI) HR (95% CI) 
Age    
 75-84 1.19 (0.98-1.44) 1.35 (1.14-1.60)* 1.14 (0.93-1.40) 
 85-94 1.34 (1.11-1.63)* 1.55 (1.31-1.83)* 1.30 (1.06-1.59)* 
 ≥ 95 1.17 (0.89-1.55) 1.47 (1.16-1.87)* 1.08 (0.80-1.46) 
 65-74 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Sex    
 Female * * * 
 Male 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Index fiscal year    
 04/05 0.98 (0.80-1.21) 1.00 (0.84-1.19) 1.02 (0.82-1.26) 
 05/06 1.00 (0.83-1.21) 1.02 (0.87-1.19) 1.00 (0.82-1.22) 
 06/07 0.87 (0.72-1.05) 0.85 (0.72-1.00) 0.81 (0.66-0.99)* 
 07/08 0.80 (0.66-0.97)* 0.85 (0.73-1.00) 0.75 (0.61-0.92)* 
 09/10 0.76 (0.63-0.93)* 0.79 (0.67-0.93)* 0.73 (0.59-0.89)* 
 10/11 0.75 (0.61-0.91)* 0.73 (0.61-0.86)* 0.76 (0.62-0.94)* 
 11/12 0.58 (0.47-0.71)* 0.56 (0.47-0.67)* 0.55 (0.44-0.69)* 
 12/13
 
- - - 
 08/09 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Comorbidity    
Dementia     
 Yes * * * 
 No 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Schizophrenia    
 Yes 1.01 (0.90-1.13) 1.03 (0.93-1.13) 1.05 (0.93-1.18) 
 No 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Mood disorder      
 Yes 0.94 (0.83-1.07) 0.96 (0.86-1.06) 0.94 (0.82-1.07) 
 No 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Alcohol or drug abuse    
 Yes 0.94 (0.65-1.37) 0.90 (0.65-1.24) 0.89 (0.59-1.33) 
 No 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Extrapyramidal symptoms     
 Yes 1.02 (0.76-1.37) 1.05 (0.82-1.34) 1.02 (0.75-1.40) 
 No 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Charlson index     
 1-2 0.94 (0.83-1.06) 0.98 (0.88-1.08) 0.93 (0.82-1.05) 
 3-4 0.99 (0.84-1.15) 1.03 (0.90-1.17) 0.95 (0.81-1.13) 
 ≥ 5 0.95 (0.78-1.16) 1.00 (0.85-1.18) 0.97 (0.79-1.19) 
 0 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
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Table F1.  Continued 
Explanatory variables
a Primary 
non-exposure gap
b 
Shorter  
non-exposure gap
b 
Longer  
non-exposure gap
b 
Level of care      
 Level 2 1.46 (0.91-2.33) 1.32 (0.90-1.95) 1.64 (0.97-2.75) 
 Level 3 1.32 (0.82-2.11) 1.24 (0.84-1.84) 1.46 (0.86-2.47) 
 Level 4 1.65 (1.02-2.65)* 1.61 (1.08-2.39)* 1.83 (1.08-3.12)* 
 Level 1 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
AHFS drug category     
 4-6 0.88 (0.75-1.02) 0.90 (0.79-1.02) 0.82 (0.70-0.96)* 
 ≥ 7 0.90 (0.77-1.04) 0.93 (0.82-1.06) 0.83 (0.71-0.98)* 
 0-3 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Behavioural    
MDS-CPS    
 Moderately impaired (2-3) * * * 
 Severely impaired (4-6) * * * 
 Minimally impaired (0-1) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
MDS-CBP    
 Mild (1-4) 1.16 (1.00-1.35)* 1.21 (1.06-1.38)* 1.12 (0.95-1.31) 
 Moderate (5-9) 0.95 (0.80-1.12) 1.04 (0.90-1.20) 0.89 (0.75-1.06) 
 Severe (10-14) 0.76 (0.61-0.95)* 0.94 (0.78-1.13) 0.70 (0.55-0.89)* 
 Extreme (≥ 15) 0.73 (0.53-1.01) 0.96 (0.74-1.24) 0.66 (0.47-0.93)* 
 None (0) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Drug exposure    
Days to APM initiation after LTCF 
admission 
   
 31-90 days 0.95 (0.82-1.10) 0.89 (0.78-1.01) 0.93 (0.79-1.08) 
 > 90 days 1.07 (0.93-1.24) 1.04 (0.93-1.18) 1.10 (0.94-1.28) 
 0-30 days 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Last APM dispensation before 
LTCF admission 
 
  
 ≤ 30 days * * * 
 > 30 days * * * 
 None in previous year 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Last antidepressant dispensation 
before LTCF admission 
   
 ≤ 30 days 1.12 (0.97-1.29) 1.17 (1.04-1.32) 1.14 (0.98-1.33) 
 > 30 days 1.05 (0.89-1.23) 1.08 (0.94-1.24) 1.12 (0.94-1.34) 
 None in previous year 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Last benzodiazepine dispensation 
before LTCF admission 
   
 ≤ 30 days 0.79 (0.66-0.93)* 0.80 (0.70-0.93)* 0.86 (0.72-1.03) 
 > 30 days 0.88 (0.75-1.04) 0.90 (0.78-1.03) 0.90 (0.75-1.07) 
 None in previous year 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Last anticholinergic dispensation 
before LTCF admission 
   
 ≤ 30 days 0.78 (0.60-1.03) 0.86 (0.69-1.08) 0.77 (0.57-1.03) 
 > 30 days 0.80 (0.63-1.01) 0.83 (0.69-1.01) 0.74 (0.57-0.95)* 
 None in previous year 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Last cholinergic dispensation 
before LTCF admission 
   
 ≤ 30 days 1.31 (1.02-1.67)* 1.24 (1.00-1.54)* 1.47 (1.14-1.89)* 
 > 30 days 1.38 (1.15-1.66)* 1.28 (1.09-1.50)* 1.33 (1.09-1.63)* 
 None in previous year 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
 79 
 
 
Table F1.  Continued    
Explanatory variables
a Primary 
non-exposure gap
b 
Shorter  
non-exposure gap
b 
Longer  
non-exposure gap
b 
Health care utilization    
Transfer to new LTCF    
 Yes 0.87 (0.77-0.98)* 0.92 (0.83-1.02) 0.89 (0.78-1.01) 
 No 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Hospitalization prior to LTCF 
admission 
 
 
 
 Yes * * * 
 No 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Hospitalization after LTCF 
admission 
   
 Yes 1.12 (1.01-1.24)* 1.07 (0.98-1.17) 1.13 (1.01-1.26)* 
 No 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
LTCF    
Facility affiliation    
 Affiliate (private, non-profit) 1.16 (1.00-1.33)* 1.18 (1.04-1.33)* 1.19 (1.02-1.38)* 
 Contract (private, for profit) 0.96 (0.78-1.19) 1.00 (0.84-1.20) 0.93 (0.74-1.16) 
 Amalgamate (public) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Facility Health Region    
 Regina Qu'Appelle * * * 
 Saskatoon * * * 
 Other 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Facility size    
 Small (1-35 beds) 0.90 (0.77-1.06) 0.96 (0.84-1.09) 0.82 (0.69-0.98)* 
 Medium (36-100 beds) 1.01 (0.89-1.14) 1.01 (0.90-1.12) 0.98 (0.86-1.12) 
 Large (> 100 beds) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Time interaction with    
 Sex * * * 
 Dementia  * * * 
 MDS-CPS * * * 
 Last APM dispensation before 
LTCF admission 
* * * 
 Hospitalization prior to LTCF 
admission 
* * * 
 Facility location * * * 
Abbreviations – AHFS: American hospital formulary system, APM: antipsychotic medication, LTCF: long-
term care facility, MDS-CBP: minimum dataset challenging behaviour profile, MDS-CPS: minimum dataset 
cognitive performance scale.  Notes – a: Explanatory variables are grouped by concept, which is indicated by 
the bold-italicized terms.  b: Normal non-exposure gap is a 35 day gap period, while shorter and longer non-
exposure gap definitions refer to 0 and 70 day gaps, respectively.Symbols - *, p < 0.05. 
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Table F2.  Hazard ratios (HRs) and 95% confidence intervals (95% CIs) for covariate-time interactions from extended 
Cox model for the assessment of model sensitivity to the definition of APM discontinuation. 
 Follow-up time (days) 
 0 days 90 days 180 days 365 days 730 days 
Variables HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) 
Sex       
 Female      
  Primary non-exposure gap
a 
2.66 (2.26-3.13) 2.34 (2.01-2.72) 2.05 (1.78-2.36) 1.57 (1.38-1.77) 0.92 (0.82-1.04) 
  Short non-exposure gap
a 
2.72 (2.37-3.13) 2.38 (2.09-2.71) 2.08 (1.84-2.35) 1.58 (1.42-1.75) 0.91 (0.83-1.01) 
  Longer non-exposure gap
a 
2.81 (2.36-3.34) 2.46 (2.09-2.89) 2.15 (1.85-2.50) 1.63 (1.43-1.87) 0.95 (0.84-1.08) 
 Male  1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Dementia      
 Yes      
  Primary non-exposure gap
a 
0.86 (0.73-1.01) 0.88 (0.75-1.02) 0.89 (0.78-1.03) 0.93 (0.83-1.05) 1.01 (0.89-1.15) 
  Short non-exposure gap
a 
0.77 (0.67-0.88) 0.79 (0.69-0.90) 0.81 (0.72-0.91) 0.86 (0.78-0.95) 0.96 (0.87-1.07) 
  Longer non-exposure gap
a 
0.81 (0.68-0.97) 0.84 (0.71-0.98) 0.86 (0.74-0.99) 0.91 (0.80-1.03) 1.01 (0.88-1.16) 
 No 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
MDS-CPS      
 Moderately impaired (2-3)      
  Primary non-exposure gap
a 
4.20 (3.29-5.36) 3.42 (2.72-4.30) 2.79 (2.25-3.45) 1.83 (1.52-2.21) 0.80 (0.68-0.95) 
  Short non-exposure gap
a 
4.84 (3.90-6.01) 3.94 (3.22-4.82) 3.20 (2.65-3.87) 2.09 (1.77-2.47) 0.90 (0.78-1.04) 
  Longer non-exposure gap
a 
4.20 (3.24-5.44) 3.43 (2.69-4.36) 2.79 (2.23-3.50) 1.84 (1.51-2.25) 0.81 (0.67-0.97) 
 Severely impaired (4-6)      
  Primary non-exposure gap
a 
4.07 (3.09-5.38) 3.41 (2.63-4.41) 2.85 (2.24-3.63) 1.98 (1.60-2.44) 0.96 (0.79-1.17) 
  Short non-exposure gap
a 
4.72 (3.69-6.03) 3.90 (3.10-4.90) 3.22 (2.60-3.98) 2.17 (1.80-2.62) 1.00 (0.85-1.19) 
  Longer non-exposure gap
a 
4.12 (3.07-5.53) 3.46 (2.63-4.54) 2.90 (2.25-3.74) 2.02 (1.62-2.53) 0.99 (0.81-1.23) 
 Minimally impaired (0-1) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Last APM dispensation before LTCF admission     
 ≤ 30 days      
  Primary non-exposure gap
a 
1.43 (1.20-1.70) 1.31 (1.11-1.55) 1.21 (1.03-1.41) 1.02 (0.88-1.17) 0.72 (0.62-0.84) 
  Short non-exposure gap
a 
1.46 (1.25-1.70) 1.33 (1.15-1.53) 1.21 (1.06-1.39) 1.00 (0.89-1.13) 0.69 (0.61-0.78) 
  Longer non-exposure gap
a 
1.45 (1.21-1.75) 1.34 (1.12-1.59) 1.23 (1.04-1.45) 1.03 (0.88-1.20) 0.73 (0.62-0.85) 
 > 30 days      
  Primary non-exposure gap
a 
1.18 (0.93-1.50) 1.11 (0.89-1.39) 1.05 (0.86-1.29) 0.94 (0.78-1.12) 0.75 (0.61-0.90) 
  Short non-exposure gap
a 
1.33 (1.08-1.63) 1.24 (1.03-1.49) 1.16 (0.97-1.38) 1.01 (0.87-1.17) 0.76 (0.65-0.90) 
  Longer non-exposure gap
a 
1.24 (0.96-1.60) 1.17 (0.92-1.48) 1.10 (0.88-1.36) 0.97 (0.80-1.17) 0.75 (0.61-0.93) 
 None in previous year 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Hospitalization prior to LTCF admission     
 Yes      
  Primary non-exposure gap
a 
4.80 (3.92-5.88) 3.89 (3.23-4.70) 3.16 (2.65-3.76) 2.05 (1.76-2.39) 0.88 (0.76-1.01) 
  Short non-exposure gap
a 
4.87 (4.09-5.80) 3.96 (3.37-4.66) 3.22 (2.77-3.74) 2.11 (1.85-2.40) 0.91 (0.81-1.03) 
  Longer non-exposure gap
a 
4.72 (3.81-5.86) 3.82 (3.13-4.66) 3.09 (2.57-3.72) 2.00 (1.70-2.35 0.85 (0.73-0.99) 
 No 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Facility Health Region      
 Regina Qu'Appelle      
  Primary non-exposure gap
a 
1.26 (1.01-1.57) 1.21 (0.99-1.49) 1.17 (0.97-1.41) 1.08 (0.91-1.28) 0.93 (0.78-1.11) 
  Short non-exposure gap
a 
1.13 (0.94-1.37) 1.09 (0.91-1.30) 1.05 (0.89-1.24) 0.98 (0.84-1.13) 0.84 (0.72-0.98) 
  Longer non-exposure gap
a 
1.16 (0.92-1.46) 1.13 (0.91-1.40) 1.10 (0.90-1.35) 1.05 (0.87-1.26) 0.95 (0.79-1.14) 
 Saskatoon      
  Primary non-exposure gap
a 
1.59 (1.30-1.95) 1.48 (1.23-1.78) 1.37 (1.16-1.63) 1.18 (1.01-1.38) 0.87 (0.74-1.04) 
  Short non-exposure gap
a 
1.38 (1.16-1.65) 1.29 (1.10-1.52) 1.20 (1.03-1.39) 1.04 (0.91-1.18) 0.77 (0.67-0.90) 
  Longer non-exposure gap
a 
1.58 (1.28-1.96) 1.47 (1.21-1.79) 1.37 (1.14-1.64) 1.18 (1.00-1.38) 0.87 (0.73-1.05) 
 Other 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Abbreviations – APM: antipsychotic medication, LTCF: long-term care facility, MDS-CPS: minimum dataset cognitive 
performance scale.  Notes – a: Primary, shorter and longer non-exposure gaps were 35, 0, and 70 days, respectively. 
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APPENDIX G – EVALUATION OF STUDY RESULTS UNDER CONDITIONS THAT 
VIOLATE THE INDEPENDENT CENSORING ASSUMPTION 
 
Table G1.  Fully adjusted Cox proportional hazards regression models with covariate time 
interactions for the assessment of independent censoring. 
Explanatory variables
a 
Primary analysis 
Positive correlation 
analysis
 
Negative correlation 
analysis
 
Demographic  HR (95% CI) HR (95% CI) HR (95% CI) 
Age    
 75-84 1.19 (0.98-1.44) 1.31 (1.21-1.43)* 1.00 (0.93-1.09) 
 85-94 1.34 (1.11-1.63)* 1.44 (1.32-1.58)* 1.02 (0.94-1.11) 
 ≥ 95 1.17 (0.89-1.55) 1.44 (1.27-1.64)* 1.02 (0.90-1.15) 
 65-74 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Sex    
 Female * * * 
 Male 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Index fiscal year    
 04/05 0.98 (0.80-1.21) 0.99 (0.90-1.10) 1.02 (0.92-1.13) 
 05/06 1.00 (0.83-1.21) 0.90 (0.82-1.00)* 0.99 (0.90-1.09) 
 06/07 0.87 (0.72-1.05) 0.90 (0.82-0.99)* 1.02 (0.93-1.12) 
 07/08 0.80 (0.66-0.97)* 1.01 (0.92-1.11) 1.02 (0.94-1.12) 
 09/10 0.76 (0.63-0.93)* 1.04 (0.95-1.13) 0.99 (0.90-1.08) 
 10/11 0.75 (0.61-0.91)* 1.05 (0.96-1.15) 1.03 (0.94-1.13) 
 11/12 0.58 (0.47-0.71)* 1.06 (0.97-1.16) 1.01 (0.92-1.10) 
 12/13
 
- - - 
 08/09 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Comorbidity     
Dementia     
 Yes - * - 
 No 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Schizophrenia    
 Yes 1.01 (0.90-1.13) 1.06 (1.00-1.11)* 0.98 (0.94-1.03) 
 No 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Mood disorder      
 Yes 0.94 (0.83-1.07) 0.99 (0.94-1.05) 1.01 (0.95-1.06) 
 No 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Alcohol or drug abuse    
 Yes 0.94 (0.65-1.37) 0.93 (0.79-1.09) 0.96 (0.82-1.12) 
 No 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Extrapyramidal symptoms     
 Yes 1.02 (0.76-1.37) 1.12 (0.99-1.27) 1.01 (0.90-1.14) 
 No 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Charlson index     
 1-2 0.94 (0.83-1.06) 0.98 (0.93-1.04) 0.99 (0.94-1.05) 
 3-4 0.99 (0.84-1.15) 1.00 (0.93-1.07) 0.98 (0.92-1.06) 
 ≥ 5 0.95 (0.78-1.16) 0.97 (0.89-1.06) 0.98 (0.89-1.07) 
 0 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
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Table G1  Continued    
Explanatory variables
a 
Primary analysis 
Positive correlation 
analysis
 
Negative correlation 
analysis
 
Level of care      
 Level 2 1.46 (0.91-2.33) 1.01 (0.83-1.22) 1.01 (0.84-1.22) 
 Level 3 1.32 (0.82-2.11) 0.90 (0.74-1.10) 1.00 (0.82-1.21) 
 Level 4 1.65 (1.02-2.65)* 1.02 (0.84-1.25) 1.00 (0.82-1.22) 
 Level 1 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
AHFS drug category     
 4-6 0.88 (0.75-1.02) 0.96 (0.90-1.03) 0.97 (0.91-1.04) 
 ≥ 7 0.90 (0.77-1.04) 0.97 (0.91-1.04) 1.00 (0.93-1.07) 
 0-3 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Behavioural     
MDS-CPS    
 Moderately impaired (2-3) * * * 
 Severely impaired (4-6) * * * 
 Minimally impaired (0-1) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
MDS-CBP    
 Mild (1-4) 1.16 (1.00-1.35)* 1.19 (1.10-1.28)* 1.01 (0.94-1.08) 
 Moderate (5-9) 0.95 (0.80-1.12) 1.13 (1.04-1.22)* 0.99 (0.91-1.06) 
 Severe (10-14) 0.76 (0.61-0.95)* 1.21 (1.10-1.33)* 1.00 (0.91-1.10) 
 Extreme (≥ 15) 0.73 (0.53-1.01) 1.28 (1.13-1.46)* 0.99 (0.88-1.12) 
 None (0) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Drug exposure     
Days to APM initiation after LTCF admission   
 31-90 days 0.95 (0.82-1.10) 0.93 (0.87-0.99)* 0.97 (0.91-1.03) 
 > 90 days 1.07 (0.93-1.24) 0.88 (0.82-0.94)* 1.01 (0.94-1.08) 
 0-30 days 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Last APM dispensation before LTCF admission   
 ≤ 30 days * * * 
 > 30 days - * * 
 None in previous year 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Last antidepressant dispensation before LTCF admission  
 ≤ 30 days 1.12 (0.97-1.29) 1.06 (0.99-1.13) 1.01 (0.95-1.08) 
 > 30 days 1.05 (0.89-1.23) 1.05 (0.98-1.13) 1.00 (0.93-1.08) 
 None in previous year 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Last benzodiazepine dispensation before LTCF admission  
 ≤ 30 days 0.79 (0.66-0.93)* 0.92 (0.85-0.99)* 1.00 (0.93-1.07) 
 > 30 days 0.88 (0.75-1.04) 0.97 (0.90-1.04) 1.01 (0.94-1.08) 
 None in previous year 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Last anticholinergic dispensation before LTCF admission  
 ≤ 30 days 0.78 (0.60-1.03) 1.03 (0.92-1.15) 1.02 (0.91-1.14) 
 > 30 days 0.80 (0.63-1.01) 1.09 (0.99-1.19) 0.99 (0.90-1.09) 
 None in previous year 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Last cholinergic dispensation before LTCF admission  
 ≤ 30 days 1.31 (1.02-1.67)* 1.10 (0.98-1.24) 1.02 (0.91-1.15) 
 > 30 days 1.38 (1.15-1.66)* 1.07 (0.98-1.17) 1.04 (0.95-1.14) 
 None in previous year 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Health care utilization     
Transfer to new LTCF    
 Yes 0.87 (0.77-0.98)* 0.96 (0.91-1.01) 1.01 (0.96-1.07) 
 No 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
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Table G1  Continued    
Explanatory variables
a 
Primary analysis 
Positive correlation 
analysis
 
Negative correlation 
analysis
 
Hospitalization prior to LTCF 
admission 
   
 Yes * * * 
 No 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Hospitalization after LTCF 
admission 
   
 Yes 1.12 (1.01-1.24)* 0.94 (0.89-0.98)* 1.01 (0.96-1.06) 
 No 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
LTCF     
Facility affiliation    
 Affiliate (private, non-profit) 1.16 (1.00-1.33)* 1.10 (1.03-1.18)* 1.02 (0.96-1.09) 
 Contract (private, for profit) 0.96 (0.78-1.19) 1.09 (0.99-1.19)* 1.01 (0.92-1.10) 
 Amalgamate (public) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Facility Health Region    
 Regina Qu'Appelle * * * 
 Saskatoon * * * 
 Other 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Facility size    
 Small (1-35 beds) 0.90 (0.77-1.06) 1.04 (0.97-1.11) 1.00 (0.93-1.07) 
 Medium (36-100 beds) 1.01 (0.89-1.14) 1.05 (0.99-1.11) 1.00 (0.95-1.06) 
 Large (> 100 beds) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Time interaction with    
 Sex * * * 
 Dementia  * - - 
 MDS-CPS * * * 
 Last APM dispensation 
before LTCF admission 
* * * 
 Hospitalization prior to 
LTCF admission 
* * * 
 Facility location * * * 
Abbreviations – AHFS: American hospital formulary system, APM: antipsychotic medication, 
LTCF: long-term care facility, MDS-CBP: minimum dataset challenging behaviour profile, 
MDS-CPS: minimum dataset cognitive performance scale.  Notes – a: Explanatory variables 
are grouped by concept, which is indicated by the bold-italicized terms.  b: Partially adjusted 
models include all group variables and demographic variables.  Therefore, the six partially 
adjusted models include the variable groups demographic, demographic + comorbidity, 
demographic + behavioural, demographic + drug exposure, demographic + health care 
utilization, and demographic + LTCF.  c: Fully adjusted models include all variables.  d: 
Covariate time interaction model is a fully adjusted model with the addition of time-covariate 
interactions.  Symbols - *, p < 0.05. 
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Table G2.  Hazard ratios (HRs) and 95% confidence intervals (95% CIs) for covariate-time interactions from extended 
Cox model for the assessment of independent censoring. 
 Follow-up time (days) 
 0 days 90 days 180 days 365 days 730 days 
Variables HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) 
Sex       
 Female      
  Primary analysis 2.66 (2.26-3.13) 2.34 (2.01-2.72) 2.05 (1.78-2.36) 1.57 (1.38-1.77) 0.92 (0.82-1.04) 
  Positive correlation analysis 2.36 (2.18-2.55) 2.08 (1.94-2.24) 1.84 (1.72-1.97) 1.42 (1.34-1.51) 0.86 (0.82-0.91) 
  Negative correlation analysis 2.45 (2.09-2.87) 2.38 (2.04-2.77) 2.31 (1.99-2.69) 2.18 (1.89-2.51) 1.94 (1.72-2.20) 
 Male  1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Dementia      
 Yes      
  Primary analysis 0.86 (0.73-1.01) 0.88 (0.75-1.02) 0.89 (0.78-1.03) 0.93 (0.83-1.05) 1.01 (0.89-1.15) 
  Positive correlation analysis 0.87 (0.81-0.95) 0.88 (0.82-0.95) 0.88 (0.83-0.95) 0.89 (0.84-0.95) 0.92 (0.87-0.97) 
  Negative correlation analysis 0.90 (0.78-1.03) 0.90 (0.79-1.03) 0.90 (0.79-1.03) 0.91 (0.80-1.03) 0.92 (0.83-1.02) 
 No 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
MDS-CPS      
 Moderately impaired (2-3)      
  Primary analysis 4.20 (3.29-5.36) 3.42 (2.72-4.30) 2.79 (2.25-3.45) 1.83 (1.52-2.21) 0.80 (0.68-0.95) 
  Positive correlation analysis 7.24 (6.32-8.30) 5.89 (5.18-6.70) 4.79 (4.24-5.41) 3.13 (2.82-3.49) 1.36 (1.24-1.48) 
  Negative correlation analysis 63.7 (46.1-88.1) 56.4 (41.2-77.3) 49.9 (36.7-67.8) 38.8 (29.1-51.8) 23.7 (18.4-30.5) 
 Severely impaired (4-6)      
  Primary analysis 4.07 (3.09-5.38) 3.41 (2.63-4.41) 2.85 (2.24-3.63) 1.98 (1.60-2.44) 0.96 (0.79-1.17) 
  Positive correlation analysis 7.10 (6.10-8.26) 5.79 (5.03-6.67) 4.73 (4.14-5.40) 3.11 (2.77-3.50) 1.37 (1.24-1.51) 
  Negative correlation analysis 59.1 (42.1-83.0) 52.5 (37.7-73.0) 46.5 (33.8-64.2) 36.4 (26.9-49.2) 22.4 (17.1-29.2) 
 Minimally impaired (0-1) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Last APM dispensation before LTCF admission     
 ≤ 30 days      
  Primary analysis 1.43 (1.20-1.70) 1.31 (1.11-1.55) 1.21 (1.03-1.41) 1.02 (0.88-1.17) 0.72 (0.62-0.84) 
  Positive correlation analysis 1.85 (1.70-2.01) 1.67 (1.54-1.81) 1.50 (1.40-1.62) 1.22 (1.14-1.30) 0.80 (0.75-0.85) 
  Negative correlation analysis 1.48 (1.28-1.71) 1.46 (1.27-1.68) 1.44 (1.26-1.65) 1.40 (1.23-1.59) 1.33 (1.18-1.49) 
 > 30 days      
  Primary analysis 1.18 (0.93-1.50) 1.11 (0.89-1.39) 1.05 (0.86-1.29) 0.94 (0.78-1.12) 0.75 (0.61-0.90) 
  Positive correlation analysis 1.56 (1.40-1.74) 1.45 (1.31-1.60) 1.35 (1.23-1.48) 1.16 (1.07-1.26) 0.87 (0.80-0.94) 
  Negative correlation analysis 1.55 (1.28-1.89) 1.53 (1.27-1.86) 1.51 (1.25-1.82) 1.47 (1.23-1.75) 1.39 (1.19-1.62) 
 None in previous year 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Hospitalization prior to LTCF admission     
 Yes      
  Primary analysis 4.80 (3.92-5.88) 3.89 (3.23-4.70) 3.16 (2.65-3.76) 2.05 (1.76-2.39) 0.88 (0.76-1.01) 
  Positive correlation analysis 4.80 (4.36-5.27) 4.06 (3.71-4.44) 3.43 (3.16-3.73) 2.44 (2.26-2.62) 1.24 (1.16-1.32) 
  Negative correlation analysis 4.18 (3.50-4.99) 3.99 (3.36-4.75) 3.82 (3.23-4.52) 3.48 (2.97-4.08) 2.90 (2.53-3.34) 
 No 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Facility Health Region      
 Regina Qu'Appelle      
  Primary analysis 1.26 (1.01-1.57) 1.21 (0.99-1.49) 1.17 (0.97-1.41) 1.08 (0.91-1.28) 0.93 (0.78-1.11) 
  Positive correlation analysis 1.47 (1.33-1.63) 1.39 (1.27-1.53) 1.32 (1.21-1.45) 1.18 (1.09-1.28) 0.95 (0.88-1.03) 
  Negative correlation analysis 1.35 (1.13-1.61) 1.34 (1.13-1.59) 1.32 (1.12-1.56) 1.29 (1.11-1.51) 1.24 (1.08-1.42) 
 Saskatoon      
  Primary analysis 1.59 (1.30-1.95) 1.48 (1.23-1.78) 1.37 (1.16-1.63) 1.18 (1.01-1.38) 0.87 (0.74-1.04) 
  Positive correlation analysis 1.41 (1.28-1.55) 1.35 (1.23-1.48) 1.29 (1.19-1.41) 1.18 (1.10-1.27) 0.99 (0.92-1.06) 
  Negative correlation analysis 1.75 (1.50-2.03) 1.72 (1.48-1.99) 1.69 (1.46-1.95) 1.63 (1.42-1.86) 1.52 (1.35-1.71) 
 Other 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Abbreviations – APM: antipsychotic medication, HR (95% CI): Hazard ratio (95% confidence interval), LTCF: long-
term care facility, MDS-CPS: minimum dataset cognitive performance scale. 
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APPENDIX H – MODEL RESULTS WHEN FOLLOW-UP WAS TRUNCATED AT 6 
MONTHS 
 
Table H1.  Hazards ratios (HRs) and 95% confidence intervals (95% CIs) when follow-up 
time was truncated at 6 months. 
Explanatory variables
a 
Full Full-interaction 
6-month  
follow-up time
 
Demographic  HR (95% CI) HR (95% CI) HR (95% CI) 
Age    
 75-84 1.10 (0.91-1.31) 1.19 (0.98-1.44) 1.19 (0.89-1.59) 
 85-94 1.38 (1.15-1.65)* 1.34 (1.11-1.63)* 1.54 (1.15-2.05)* 
 ≥ 95 1.53 (1.16-2.01)* 1.17 (0.89-1.55) 1.69 (1.15-2.49)* 
 65-74 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Sex    
 Female 0.93 (0.83-1.04) * 0.83 (0.71-0.97)* 
 Male 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Index fiscal year    
 04/05 0.77 (0.63-0.95)* 0.98 (0.80-1.21) 0.88 (0.64-1.23) 
 05/06 1.02 (0.85-1.23) 1.00 (0.83-1.21) 1.11 (0.83-1.48) 
 06/07 0.96 (0.80-1.15) 0.87 (0.72-1.05) 1.00 (0.75-1.33) 
 07/08 0.84 (0.69-1.01) 0.80 (0.66-0.97)* 0.96 (0.72-1.29) 
 09/10 0.89 (0.73-1.08) 0.76 (0.63-0.93)* 0.92 (0.69-1.23) 
 10/11 0.94 (0.77-1.14) 0.75 (0.61-0.91)* 1.07 (0.81-1.40) 
 11/12 0.97 (0.79-1.19) 0.58 (0.47-0.71)* 1.06 (0.80-1.40) 
 12/13
 
- - - 
 08/09 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Comorbidity     
Dementia     
 Yes 1.03 (0.92-1.15) * 0.96 (0.81-1.13) 
 No 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Schizophrenia    
 Yes 0.88 (0.79-0.98)* 1.01 (0.90-1.13) 0.84 (0.72-0.99)* 
 No 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Mood disorder      
 Yes 0.84 (0.74-0.95)* 0.94 (0.83-1.07) 0.79 (0.66-0.95)* 
 No 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Alcohol or drug abuse    
 Yes 0.84 (0.58-1.22) 0.94 (0.65-1.37) 1.06 (0.64-1.77) 
 No 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Extrapyramidal symptoms     
 Yes 0.87 (0.65-1.17) 1.02 (0.76-1.37) 1.03 (0.67-1.57) 
 No 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Charlson index     
 1-2 0.94 (0.83-1.05) 0.94 (0.83-1.06) 0.90 (0.76-1.07) 
 3-4 0.98 (0.84-1.15) 0.99 (0.84-1.15) 0.93 (0.75-1.17) 
 ≥ 5 1.00 (0.82-1.21) 0.95 (0.78-1.16) 1.01 (0.76-1.33) 
 0 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Level of care      
 Level 2 1.74 (1.10-2.76)* 1.46 (0.91-2.33) 1.49 (0.72-3.06) 
 Level 3 1.70 (1.07-2.71)* 1.32 (0.82-2.11) 1.40 (0.67-2.92) 
 Level 4 2.03 (1.27-3.24)* 1.65 (1.02-2.65)* 1.74 (0.84-3.62) 
 Level 1 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
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Table H1. Continued    
Explanatory variables
a 
Full Full-interaction 
6-month  
follow-up time
 
AHFS drug category     
 4-6 0.94 (0.81-1.09) 0.88 (0.75-1.02) 0.85 (0.69-1.06) 
 ≥ 7 1.11 (0.96-1.29) 0.90 (0.77-1.04) 1.07 (0.86-1.32) 
 0-3 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Behavioural     
MDS-CPS    
 Moderately impaired (2-3) 0.87 (0.75-1.01) * 0.76 (0.63-0.93)* 
 Severely impaired (4-6) 1.11 (0.93-1.32) * 0.82 (0.64-1.05) 
 Minimally impaired (0-1) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
MDS-CBP    
 Mild (1-4) 1.02 (0.88-1.17) 1.16 (1.00-1.35)* 0.99 (0.81-1.20) 
 Moderate (5-9) 0.86 (0.73-1.00) 0.95 (0.80-1.12) 0.71 (0.56-0.90)* 
 Severe (10-14) 0.64 (0.51-0.79)* 0.76 (0.61-0.95)* 0.55 (0.39-0.76)* 
 Extreme (≥ 15) 0.59 (0.43-0.81)* 0.73 (0.53-1.01) 0.49 (0.30-0.81)* 
 None (0) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Drug exposure     
Days to APM initiation after LTCF admission   
 31-90 days 1.01 (0.88-1.17) 0.95 (0.82-1.10) 0.91 (0.74-1.13) 
 > 90 days 1.16 (1.01-1.33)* 1.07 (0.93-1.24) 1.09 (0.89-1.32) 
 0-30 days 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Last APM dispensation before LTCF admission   
 ≤ 30 days 0.75 (0.65-0.86)* * 0.59 (0.48-0.73)* 
 > 30 days 0.72 (0.60-0.85)* * 0.61 (0.48-0.79)* 
 None in previous year 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Last antidepressant dispensation before LTCF admission  
 ≤ 30 days 0.94 (0.82-1.09) 1.12 (0.97-1.29) 1.06 (0.86-1.32) 
 > 30 days 1.03 (0.88-1.22) 1.05 (0.89-1.23) 1.10 (0.88-1.39) 
 None in previous year 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Last benzodiazepine dispensation before LTCF admission  
 ≤ 30 days 0.80 (0.68-0.95)* 0.79 (0.66-0.93)* 0.80 (0.61-1.03) 
 > 30 days 0.86 (0.73-1.01) 0.88 (0.75-1.04) 0.93 (0.73-1.18) 
 None in previous year 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Last anticholinergic dispensation before LTCF admission  
 ≤ 30 days 0.81 (0.62-1.07) 0.78 (0.60-1.03) 1.01 (0.71-1.45) 
 > 30 days 0.79 (0.63-1.00)* 0.80 (0.63-1.01) 0.80 (0.58-1.11) 
 None in previous year 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Last cholinergic dispensation before LTCF admission  
 ≤ 30 days 1.22 (0.96-1.56) 1.31 (1.02-1.67)* 0.94 (0.61-1.44) 
 > 30 days 1.40 (1.16-1.67)* 1.38 (1.15-1.66)* 1.60 (1.22-2.10)* 
 None in previous year 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Health care utilization    
Transfer to new LTCF    
 Yes 0.91 (0.81-1.02) 0.87 (0.77-0.98)* 0.96 (0.81-1.14) 
 No 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Hospitalization prior to LTCF 
admission 
   
 Yes 1.10 (0.97-1.24) * 1.29 (1.06-1.56)* 
 No 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Hospitalization after LTCF 
admission 
   
 Yes 1.13 (1.02-1.26)* 1.12 (1.01-1.24)* 1.12 (0.96-1.30) 
 No 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
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Table H1. Continued    
Explanatory variables
a 
Full Full-interaction 
6-month  
follow-up time
 
LTCF     
Facility affiliation    
 Affiliate (private, non-profit) 1.09 (0.95-1.25) 1.16 (1.00-1.33)* 1.24 (1.02-1.52)* 
 Contract (private, for profit) 1.09 (0.89-1.34) 0.96 (0.78-1.19) 1.33 (0.99-1.77) 
 Amalgamate (public) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Facility Health Region    
 Regina Qu'Appelle 0.98 (0.83-1.16) * 0.80 (0.63-1.03) 
 Saskatoon 1.10 (0.95-1.27) * 1.20 (0.97-1.48) 
 Other 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Facility size    
 Small (1-35 beds) 0.92 (0.79-1.07) 0.90 (0.77-1.06) 1.03 (0.83-1.29) 
 Medium (36-100 beds) 1.02 (0.90-1.15) 1.01 (0.89-1.14) 1.01 (0.84-1.22) 
 Large (> 100 beds) 1.00 (Ref) 1.00 (Ref) 1.00 (Ref) 
Time interaction with    
 Sex N/A * N/A 
 Dementia  N/A * N/A 
 MDS-CPS N/A * N/A 
 Last APM dispensation 
before LTCF admission 
N/A * N/A 
 Hospitalization prior to 
LTCF admission 
N/A * N/A 
 Facility location N/A * N/A 
Abbreviations – AHFS: American hospital formulary system, APM: antipsychotic medication, 
LTCF: long-term care facility, MDS-CBP: minimum dataset challenging behaviour profile, 
MDS-CPS: minimum dataset cognitive performance scale.  Notes – a: Explanatory variables 
are grouped by concept, which is indicated by the bold-italicized terms.  c: Fully adjusted 
models include all variables.  d: Covariate time interaction model is a fully adjusted model 
with the addition of time-covariate interactions.  Symbols - *, p < 0.05. 
 
 
